US20240003056A1 - Anti-talen antibodies and uses thereof - Google Patents

Anti-talen antibodies and uses thereof Download PDF

Info

Publication number
US20240003056A1
US20240003056A1 US18/354,037 US202318354037A US2024003056A1 US 20240003056 A1 US20240003056 A1 US 20240003056A1 US 202318354037 A US202318354037 A US 202318354037A US 2024003056 A1 US2024003056 A1 US 2024003056A1
Authority
US
United States
Prior art keywords
seq
antibody
amino acid
acid sequence
talen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
US18/354,037
Inventor
Thomas Charles Pertel
Barbra Johnson Sasu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allogene Therapeutics Inc
Original Assignee
Allogene Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allogene Therapeutics Inc filed Critical Allogene Therapeutics Inc
Priority to US18/354,037 priority Critical patent/US20240003056A1/en
Publication of US20240003056A1 publication Critical patent/US20240003056A1/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/10—Libraries containing peptides or polypeptides, or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • the .xml file contains a sequence listing entitled “AT-021_03_SL.xml” created on Jul. 17, 2023, and having a size of 38,698 bytes.
  • the sequence listing contained in this .xml file is part of the specification and is incorporated herein by reference in its entirety.
  • the present disclosure relates to antigen binding molecules, including, but not limited to, antibodies, which specifically bind gene editing proteins (e.g., TALEN proteins comprising a FokI, also referred to as Fok-1 or Fok1, catalytic domain) and polynucleotides encoding the same, and methods of use.
  • gene editing proteins e.g., TALEN proteins comprising a FokI, also referred to as Fok-1 or Fok1, catalytic domain
  • polynucleotides encoding the same and methods of use.
  • Genome editing tools such as Transcription activator-like effector nucleases (TALEN®), Zinc-finger nucleases (ZFNs), and RNA-guided FokI Nucleases (RFNs) are powerful tools that enable the precise revision, insertion or deletion of genes.
  • TALENs, ZFNs, and RFNs can bind to and cleave at targeted sites in a genome.
  • the resulting cleaved DNA is repaired via the endogenous cell DNA repair mechanism of non-homologous end joining (NHEJ), or via homology-directed repair (HDR) when a repair template is provided.
  • TALENs use a TAL effector DNA-binding domain fused to a DNA cleavage domain (e.g., FokI).
  • ZFNs are composed of a restriction endonuclease cleavage or catalytic domain, such as FokI, linked to engineered Cys 2 His 2 zinc-finger, DNA-binding polypeptides.
  • RFNs are composed of a FokI nuclease fused to catalytically inactive form of Cas9.
  • mammals e.g., humans, dogs, cattle, non-human primates, etc.
  • TALENs, ZFNs and RFNs will be expressed at high level.
  • the present disclosure provides, among other things, antibodies for the detection of FokI catalytic domains and full-length TALEN proteins in a sample. As described herein, including in the Examples below, the present disclosure provides anti-TALEN antibodies which specifically bind TALEN and FokI proteins. In some embodiments anti-TALEN antibodies of the present disclosure can be used to evaluate gene editing therapies and processes.
  • the instant disclosure provides an anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO: 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO: 7.
  • the anti-TALEN antibody is humanized.
  • the antibody is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′) 2 , a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.
  • the antibody comprises a variable heavy chain (HC) selected from the group consisting of SEQ ID NOs: 3-6
  • the anti-TALEN antibody comprises a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 12-14, and/or a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 15-20, and/or a heavy chain CDR3 comprising SEQ ID NO: 21.
  • an anti-TALEN antibody comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table 1c.
  • an anti-TALEN antibody comprising a VH amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule provided herein.
  • an anti-TALEN antibody comprises a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11.
  • an anti-TALEN antibody comprises a light chain CDR1 comprising SEQ ID NO: 22, and/or a light chain CDR2 selected from the group consisting of SEQ ID NO: 23-25, and/or a light chain CDR3 selected from the group consisting of SEQ ID NOs: 26-28.
  • the light chain comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, each CDR comprising an amino acid sequence in Table ld.
  • an anti-TALEN antibody comprising a VL amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL of an antigen binding molecule provided herein.
  • an anti-TALEN antibody comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d)a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26 and in a further embodiment, an anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 7.
  • an anti-TALEN antibody comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment an anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 8.
  • an anti-TALEN antibody comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26, and in a further embodiment the anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 9.
  • an anti-TALEN antibody In still a further embodiment, provided herein is an anti-TALEN antibody
  • the anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 5; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 10.
  • an anti-TALEN antibody comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment the anti-TALEN antibody of claim 23 , comprising (a) a VH comprising the amino acid sequence of SEQ ID NO: 6; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 11.
  • the anti-TALEN antibody further comprises a detectable label, and in some embodiments the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
  • the fluorescent label can be selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cer
  • composition comprising an anti-TALEN antibody provided herein and an acceptable carrier or vehicle, e.g., a pharmaceutically acceptable carrier or vehicle.
  • Polynucleotides encoding the heavy chain of an anti-TALEN antibody disclosed herein are also provided.
  • Polynucleotide encoding the light chain of an anti-TALEN antibody disclosed herein are also provided.
  • Vectors comprising one or both of the heavy and light chain encoding polynucleotides are also provided.
  • a cell comprising one or both of the vectors is provided, and the cell can comprise a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell.
  • a method of making an anti-TALEN antibody disclosed herein is provided and comprises incubating a cell comprising one or both of the vectors described above under suitable conditions.
  • the absence of a TALEN protein in a sample comprises contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample; in some embodiments the anti-TALEN antibody comprises an antibody provided herein, or a humanized form thereof.
  • the sample can be a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.
  • FIG. 1 depicts a Western blot analysis of hybridoma supernatants from fusion #2299 (Numbers 13-16 noted in the figure) and #2296 (Numbers 3, 6, 7, 8, and 11 noted in the figure).
  • affinity refers to a measure of the tightness that a particular ligand binds to its partner. Affinities can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some embodiments, binding partner concentration and/or ligand concentration can be varied. In some such embodiments, affinity can be compared to a reference under comparable conditions (e.g., concentrations).
  • Amino acid in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds.
  • an amino acid has the general structure H 2 N—C(H)(R)—COOH.
  • an amino acid is a naturally-occurring amino acid.
  • an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid.
  • standard amino acid refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides.
  • nonstandard amino acid refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source.
  • an amino acid including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above.
  • an amino acid can be modified by methylation, amidation, acetylation, and/or substitution as compared with the general structure.
  • amino acid is used to refer to a free amino acid; in some embodiments it is used to refer to an amino acid residue of a polypeptide.
  • Antibody refers to a species of antigen binding proteins comprising a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer specific binding to a particular target antigen.
  • intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a “Y-shaped” structure.
  • Each heavy chain is comprised of at least four domains (each about 110 amino acids long), an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CH1, CH2, and the carboxy-terminal CH3 (located at the base of the Y′s stem).
  • VH amino-terminal variable
  • CH1, CH2 amino-terminal variable
  • CH3 carboxy-terminal CH3
  • Each light chain is comprised of two domains—an amino-terminal variable (VL) domain, followed by a carboxy-terminal constant (CL) domain, separated from one another by another “switch”.
  • VL amino-terminal variable
  • CL carboxy-terminal constant
  • Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed.
  • Naturally-produced antibodies are also glycosylated, typically on the CH2 domain.
  • Each domain in a natural antibody has a structure characterized by an “immunoglobulin fold” formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel.
  • Each variable domain contains three hypervariable loops known as “complement determining regions” (CDR1, CDR2, and CDR3) and four somewhat invariant “framework” regions (FR1, FR2, FR3, and FR4).
  • CDR1, CDR2, and CDR3 three hypervariable loops known as “complement determining regions” (CDR1, CDR2, and CDR3) and four somewhat invariant “framework” regions (FR1, FR2, FR3, and FR4).
  • the Fc region of naturally-occurring antibodies binds to elements of the complement system, and also to receptors on effector cells, including for example effector cells that mediate cytotoxicity.
  • an antibody is polyclonal; in some embodiments, an antibody is monoclonal.
  • Binding typically refers to a non-covalent association between or among two or more entities. “Direct” binding involves physical contact between entities or moieties; “indirect” binding involves physical interaction by way of physical contact with one or more intermediate entities.
  • Chromosome refers to a linear molecule of DNA with associated proteins in the nucleus of eukaryotic cells that carries the genes and functions in the transmission of hereditary information.
  • residues in a polypeptide are often designated using a canonical numbering system based on a reference related polypeptide, so that an amino acid “corresponding to” a residue at position 190, for example, need not actually be the 190 th amino acid in a particular amino acid chain but rather corresponds to the residue found at 190 in the reference polypeptide; those of ordinary skill in the art readily appreciate how to identify “corresponding” amino acids.
  • Detection moiety refers to any element, molecule, functional group, compound, fragment or moiety that is detectable. In some embodiments, a detection moiety is provided or utilized alone. In some embodiments, a detection moiety is provided and/or utilized in association with (e.g., joined to) another agent.
  • detection moieties include, but are not limited to: various ligands, radionuclides (e.g., 3 H, 14 C, 18 F, 19 F, 32 P, 35 S, 135 I, 125 I, 123 I, 64 Cu, 187 Re, 111 In, 90 Y, 99m Tc, 177 Lu, 89 Zr etc.), fluorescent dyes (such as, for example fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (such as, for example, acridinum esters, stabilized dioxetanes, and the like), electrochemiluminescent agents (such as, for example, Sulfo Tags), bioluminescent agents (such as, for example, luciferin), spectrally resolvable inorganic fluorescent semiconductors nanocrystals (i.e., quantum dots), metal nanoparticles (e.g.,
  • an engineered polynucleotide refers to the aspect of having been manipulated by the hand of man.
  • a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide.
  • an engineered polynucleotide can comprise a regulatory sequence that is found in nature in operative association with a first coding sequence but not in operative association with a second coding sequence, is linked by the hand of man so that it is operatively associated with the second coding sequence.
  • a cell or organism is considered to be “engineered” if it has been manipulated so that its genetic information is altered (e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or by a deletion mutation, or by mating protocols).
  • new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or by a deletion mutation, or by mating protocols.
  • progeny of an engineered polynucleotide or cell are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.
  • expression of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or 3′ end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
  • FokI As used herein, the term “FokI” (alternatively referred to as Fok1 or Fok-1) refers to a bacterial type IIS restriction endonuclease that is naturally found in Flavobacterium okeanokoites. Natural FokI comprises of an N-terminal DNA-binding domain and a non-specific DNA cleavage domain at the C-terminus. The FokI DNA cleavage domain can function independently of the DNA binding domain. As used herein, FokI refers to a protein or a nucleic acid encoding a protein that comprises the DNA cleavage domain (i.e., the nuclease domain) of FokI.
  • FokI can refer to the entire FokI protein (SEQ ID NO: 2) or just the catalytic nuclease domain (SEQ ID NO: 1).
  • the term “FokI” refers to all fragments and variants of FokI including mutants, derivatives, analogs, truncations, fusion constructs, and multimers of FokI, including FokI dimers.
  • FokI is recombinantly produced.
  • a FokI polypeptide is conjugated to or tagged with an additional moiety, such as a binding moiety and/or a detection moiety.
  • the term “FokI” is used to refer to the FokI polypeptide or fragments or variants thereof in some embodiments “FokI” is used to refer to nucleic acids encoding a FokI polypeptide and fragments and variants thereof.
  • a “fragment” of a biological molecule as described herein has a structure that includes a discrete portion of the whole but lacks one or more moieties found in the whole (e.g., a polypeptide lacking one or more amino acids). In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole (e.g. a polypeptide domain). In some embodiments, the biological molecule is a polymer (e.g. a nucleic acid polymer or a polypeptide).
  • a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) as found in the whole polymer.
  • monomeric units e.g., residues
  • a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer.
  • the whole biological molecule can be referred to as the “parent” of the whole.
  • a “fusion molecule” is a molecule in which two or more subunit molecules are linked, preferably covalently.
  • the subunit molecules can be the same chemical type of molecule or can be different chemical types of molecules.
  • Examples fusions of the same chemical type of molecule include, but are not limited to, fusion proteins (for example, a fusion between a Zinc Finger Protein or TALEN DNA-binding domain to a FokI cleavage domain) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra).
  • Examples fusions of different chemical types of molecule include, but are not limited to, nucleic acid-polypeptide fusions (for example, a fusion between an RNA molecule and a FokI cleavage domain).
  • a gene refers to a DNA sequence that codes for a product (e.g., an RNA product and/or a polypeptide product).
  • a gene includes coding sequence (i.e., sequence that encodes a particular product); in some embodiments, a gene includes non-coding sequence.
  • a gene can include both coding (e.g., exonic) and non-coding (e.g., intronic) sequence.
  • a gene can include one or more regulatory elements that, for example, can control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc).
  • Gene or Cell therapy refers to insertion or deletion of specific genomic DNA sequences to treat or prevent a disorder or condition for which such therapy is sought.
  • the insertion or deletion of genomic DNA sequences occurs in specific cells (i.e. target cells).
  • Target cells can be from a mammal and/or can be cells in a mammalian subject. Mammals include but are not limited to humans, dogs, cats, cows, sheep, pigs, llamas, non-human primates, etc.
  • heterologous DNA is transferred to target cells. The heterologous DNA can be introduced into the selected target cells in a manner such that the heterologous DNA is expressed, and a therapeutic product encoded thereby is produced.
  • the heterologous DNA can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product.
  • Genetic or cell therapy can also be used to deliver nucleic acid encoding a gene product that replaces a defective gene or supplements a gene product produced by the mammal or the cell in which it is introduced.
  • the heterologous DNA encoding the therapeutic product can be modified prior to introduction into the cells of the afflicted subject in order to enhance or otherwise alter the product or expression thereof.
  • Genetic or cell therapy can also involve delivery of an inhibitor or repressor or other modulator of gene expression.
  • Gene therapy can include in vivo or ex vivo techniques.
  • gene or cell therapy includes administering nucleic acids encoding Transcription activator-like effector nucleases (TALENs), Zinc-Finger Nucleases (ZFNs) or RNA-guided FokI nucleases (RFNs).
  • TALENs Transcription activator-like effector nucleases
  • ZFNs Zinc-Finger Nucleases
  • RFNs RNA-guided FokI nucleases
  • viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs or RFNs to cells in vitro.
  • Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as poloxamers or liposomes.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell.
  • Genome refers to the total genetic information carried by an individual organism or cell, represented by the complete DNA sequences of its chromosomes.
  • High affinity binding refers to a high degree of tightness with which a particular ligand binds to its partner. Affinities can be measured by any available method, including those known in the art. In some embodiments, binding is considered to be high affinity if the K d is about 500 pM or less (e.g., below about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM, about 50 pM, about 40 pM, about 30 pM, about pM, about 10 pM, about 5 pM, about 4 pM, about 3 pM, about 2 pM, etc.) in binding assays.
  • K d is about 500 pM or less (e.g., below about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60
  • binding is considered to be high affinity if the affinity is stronger (e.g., the K d is lower) for a polypeptide of interest than for a selected reference polypeptide. In some embodiments, binding is considered to be high affinity if the ratio of the K d for a polypeptide of interest to the K d for a selected reference polypeptide is 1:1 or less (e.g., 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1. 0.4:1, 0.3:1, 0.2:1, 0.1:1, 0.05:1, 0.01:1, or less).
  • binding is considered to be high affinity if the K d for a polypeptide of interest is about 100% or less (e.g., about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1% or less) of the K d for a selected reference polypeptide.
  • the K d for a polypeptide of interest is about 100% or less (e.g., about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about
  • homology refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules.
  • polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical.
  • polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similar.
  • in vitro refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.
  • In vivo refers to events that occur within a multi-cellular organism, such as a human and a non-human animal. In the context of cell-based systems, the term can be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).
  • Isolated refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities can be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated.
  • isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure.
  • a substance is “pure” if it is substantially free of other components.
  • a substance can still be considered “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients.
  • a biological polymer such as a polypeptide or polynucleotide that occurs in nature is considered to be “isolated” when, a) by virtue of its origin or source of derivation is not associated with some or all of the components that accompany it in its native state in nature; b) it is substantially free of other polypeptides or nucleic acids of the same species from the species that produces it in nature; c) is expressed by or is otherwise in association with components from a cell or other expression system that is not of the species that produces it in nature.
  • a polypeptide that is chemically synthesized or is synthesized in a cellular system different from that which produces it in nature is considered to be an “isolated” polypeptide.
  • a polypeptide that has been subjected to one or more purification techniques can be considered to be an “isolated” polypeptide to the extent that it has been separated from other components a) with which it is associated in nature; and/or b) with which it was associated when initially produced.
  • Linker is used to refer to that portion of a multi-element polypeptide that connects different elements to one another.
  • a polypeptide whose structure includes two or more functional or organizational domains often includes a stretch of amino acids between such domains that links them to one another.
  • a polypeptide comprising a linker element has an overall structure of the general form S1-L-S2, wherein S1 and S2 can be the same or different and represent two domains associated with one another by the linker.
  • a linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids in length.
  • a linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but rather provides flexibility to the polypeptide.
  • linker elements that can appropriately be used when engineering polypeptides (e.g., fusion polypeptides) known in the art (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2: 1 121-1123).
  • nucleic acid refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain.
  • a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage.
  • nucleic acid refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues.
  • a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns.
  • nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis.
  • a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long.
  • a nucleic acid is single stranded; in some embodiments, a nucleic acid is double stranded.
  • a nucleic acid has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a nucleic acid has enzymatic activity.
  • Physiological conditions has its art-understood meaning referencing conditions under which cells or organisms live and/or reproduce.
  • the term refers to conditions of the external or internal milieu that can occur in nature for an organism or cell system.
  • physiological conditions are those conditions present within the body of a human or non-human animal, especially those conditions present at and/or within a surgical site.
  • Physiological conditions typically include, e.g., a temperature range of about 20-about 40° C., atmospheric pressure of about 1, pH of about 6-about8, glucose concentration of about 1-about 20 mM, oxygen concentration at atmospheric levels, and gravity as it is encountered on earth.
  • conditions in a laboratory are manipulated and/or maintained at physiologic conditions.
  • physiological conditions are encountered in an organism.
  • Polypeptide generally has its art-recognized meaning of a polymer of at least three amino acids. Those of ordinary skill in the art will appreciate that the term “polypeptide” is intended to be sufficiently general as to encompass not only polypeptides having a complete sequence recited herein, but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides. Moreover, those of ordinary skill in the art understand that protein sequences generally tolerate some substitution without destroying activity.
  • Polypeptides can contain L-amino acids, D-amino acids, or both and can contain any of a variety of amino acid modifications or analogs known in the art.
  • proteins can comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof.
  • the term “peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids.
  • proteins are antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
  • Protein refers to one or more polypeptides that function as a discrete unit. If a single polypeptide is the discrete functioning unit and does not require permanent or temporary physical association with other polypeptides in order to form the discrete functioning unit, the terms “polypeptide” and “protein” can be used interchangeably. If the discrete functional unit is comprised of more than one polypeptide that physically associate with one another, the term “protein” can be used to refer to the multiple polypeptides that are physically associated and function together as the discrete unit. In some embodiments, proteins can include moieties other than amino acids (e.g., glycoproteins, proteoglycans, etc.) and/or can be otherwise processed or modified.
  • moieties other than amino acids e.g., glycoproteins, proteoglycans, etc.
  • protein can refer to a complete polypeptide chain as produced by a cell (e.g., with or without a signal sequence), and/or to a form that is active within a cell (e.g., a truncated or complexed form).
  • a protein is comprised of multiple polypeptide chains, such chains can be covalently associated with one another, for example by one or more disulfide bonds, or can be associated by other means.
  • Reference as used herein in a scientific context describes a standard or control relative to which a comparison is performed.
  • an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value.
  • a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest.
  • a reference or control is a historical reference or control, optionally embodied in a tangible medium.
  • a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment.
  • sample typically refers to a biological sample obtained or derived from a source of interest, as described herein.
  • a source of interest comprises an organism, such as an animal or human.
  • a biological sample is or comprises biological tissue or fluid.
  • a biological sample can be or comprise bone marrow; blood; blood cells of any type (e.g., T cells); ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc.
  • blood cells of any type e.g., T cells
  • ascites tissue or fine needle biopsy samples
  • cell-containing body fluids free floating nucleic acids
  • sputum saliva
  • a biological sample is or comprises cells obtained from an individual.
  • obtained cells are or include cells from an individual from whom the sample is obtained.
  • a sample is a “primary sample” obtained directly from a source of interest by any appropriate means.
  • a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc.
  • sample refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane.
  • processing e.g., by removing one or more components of and/or by adding one or more agents to
  • a primary sample For example, filtering using a semi-permeable membrane.
  • Such a “processed sample” can comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.
  • Specific binding refers to a binding agent's ability to discriminate between possible partners, in the environment in which binding is to occur.
  • a binding agent that interacts with one particular target when other potential targets are present is said to “bind specifically” to the target with which it interacts.
  • specific binding is assessed by detecting or determining degree of association between the binding agent and its partner; in some embodiments, specific binding is assessed by detecting or determining degree of dissociation of a binding agent-partner complex; in some embodiments, specific binding is assessed by detecting or determining ability of the binding agent to compete an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detections or determinations across a range of concentrations.
  • Subject is meant a mammal (e.g., a human, in some embodiments including prenatal human forms).
  • a subject is suffering from a relevant disease, disorder or condition.
  • a subject is susceptible to a disease, disorder, or condition.
  • a subject displays one or more symptoms or characteristics of a disease, disorder or condition.
  • a subject does not display any symptom or characteristic of a disease, disorder, or condition.
  • a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition.
  • a subject is a patient.
  • a subject is an individual to whom diagnosis and/or therapy is, will and/or has been administered.
  • the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest.
  • One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result.
  • the term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
  • variant refers to an entity that shows significant structural identity with a reference entity but differs structurally from the reference entity in the presence or level of one or more chemical moieties as compared with the reference entity. In many embodiments, a variant also differs functionally from its reference entity. In general, whether a particular entity is properly considered to be a “variant” of a reference entity is based on its degree of structural identity with the reference entity. As will be appreciated by those skilled in the art, any biological or chemical reference entity has certain characteristic structural elements. A variant, by definition, is a distinct chemical entity that shares one or more such characteristic structural elements.
  • a small molecule can have a characteristic core structural element (e.g., a macrocycle core) and/or one or more characteristic pendent moieties so that a variant of the small molecule is one that shares the core structural element and the characteristic pendent moieties but differs in other pendent moieties and/or in types of bonds present (e.g., single vs double, E vs Z, etc.) within the core, a polypeptide can have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular biological function, a nucleic acid can have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to on another in linear or three-dimensional space.
  • a characteristic core structural element e.g., a macrocycle core
  • one or more characteristic pendent moieties so that a variant of the small molecule is one that shares the core structural element and the characteristic pendent
  • a variant polypeptide can differ from a reference polypeptide as a result of one or more differences in amino acid sequence and/or one or more differences in chemical moieties (e.g., carbohydrates, lipids, etc.) covalently attached to the polypeptide backbone.
  • a variant polypeptide shows an overall sequence identity with a reference polypeptide that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%.
  • a variant polypeptide does not share at least one characteristic sequence element with a reference polypeptide.
  • the reference polypeptide has one or more biological activities.
  • a variant polypeptide shares one or more of the biological activities of the reference polypeptide. In some embodiments, a variant polypeptide lacks one or more of the biological activities of the reference polypeptide. In some embodiments, a variant polypeptide shows a reduced level of one or more biological activities as compared with the reference polypeptide. In many embodiments, a polypeptide of interest is considered to be a “variant” of a parent or reference polypeptide if the polypeptide of interest has an amino acid sequence that is identical to that of the parent but for a small number of sequence alterations at particular positions.
  • a variant has 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substituted residue as compared with a parent.
  • a variant has a very small number (e.g., fewer than 5, 4, 3, 2, or 1) number of substituted functional residues (i.e., residues that participate in a particular biological activity).
  • a variant typically has not more than 5, 4, 3, 2, or 1 additions or deletions, and often has no additions or deletions, as compared with the parent.
  • any additions or deletions are typically fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly are fewer than about 5, about 4, about 3, or about 2 residues.
  • the parent or reference polypeptide is one found in nature.
  • the variant is engineered. In some embodiments the variant is naturally occurring. As will be understood by those of ordinary skill in the art, a plurality of variants of a particular polypeptide of interest can be found in nature.
  • Vector refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked.
  • plasmid refers to a circular double stranded DNA loop into which additional DNA segments can be ligated.
  • viral vector e.g., a lentiviral vector or a gamma retroviral vector
  • certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors).
  • vectors e.g., non-episomal mammalian vectors
  • vectors can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome.
  • certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”
  • Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection).
  • Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein.
  • the foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.
  • Zinc finger protein refers to a polypeptide that contains a “zinc finger domain” through which it is capable of binding to nucleic acids (e.g., DNA).
  • the term “zinc finger domain” refers to an individual “finger”, which comprises a ⁇ -fold stabilized by a zinc ion. Each zinc finger domain typically includes approximately 30 amino acids. Zinc finger domains are largely structurally independent and can retain their structure and function in different environments.
  • the present disclosure provides, antibodies that bind TALEN proteins and/or the FokI catalytic DNA cleavage domain and uses thereof
  • antibodies include, but are not limited to antibody binding regions that are immunologically functional fragments.
  • immunologically functional fragment or “fragment” of an antibody is a species of antibody comprising a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is still capable of specifically binding to a target antigen (e.g., binding to FokI and/or TALEN proteins).
  • target antigen e.g., binding to FokI and/or TALEN proteins.
  • Such fragments are biologically active in that they bind to the target antigen and can compete with other antigen binding molecules, including intact antibodies, for binding to a given epitope.
  • the fragments are neutralizing fragments.
  • the fragments can block or reduce the activity of the target antigen (e.g., blocking effect).
  • the fragments can antagonize the activity the target antigen.
  • an anti-TALEN antibody of the instant disclosure is an antibody identified herein as clones 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4. and each comprises the heavy and light chain amino acid, coding, variable, and CDR sequences, as provided and labeled herein.
  • the clones 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4 specifically bind a molecule comprising a FokI catalytic domain.
  • Immunologically functional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab′, F(ab′) 2 , and the like), one or more complementarity determining regions (“CDRs”), a diabody (heavy chain variable domain on the same polypeptide as a light chain variable domain, connected via a short peptide linker that is too short to permit pairing between the two domains on the same chain), domain antibodies, bivalent antigen binding domains (comprises two antigen binding sites), multispecific antigen binding domains, and single-chain antibodies.
  • CDRs complementarity determining regions
  • diabody heavy chain variable domain on the same polypeptide as a light chain variable domain, connected via a short peptide linker that is too short to permit pairing between the two domains on the same chain
  • domain antibodies bivalent antigen binding domains (comprises two antigen binding sites), multispecific antigen binding domains, and single-chain antibodies.
  • an antigen binding molecule can include non
  • variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by the 3 hypervariable regions (CDRs).
  • the CDRs from the two chains of each pair typically are aligned by the framework regions, which can enable binding to a specific epitope.
  • both light and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4.
  • CDR regions in the heavy chain are typically referred to as HC CDR1, CDR2, and CDR3.
  • the CDR regions in the light chain are typically referred to as LC CDR1, CDR2, and CDR3.
  • anti-TALEN antibodies comprise one or more complementarity binding regions (CDRs) present in the full-length light or heavy chain of an antibody, and in some embodiments comprise a single heavy chain and/or light chain or portion thereof.
  • CDRs complementarity binding regions
  • These fragments can be produced by recombinant DNA techniques or can be produced by enzymatic or chemical cleavage of antigen binding domains, including intact antibodies.
  • the antigen binding domain is an antibody of fragment thereof, including one or more of the complementarity determining regions (CDRs) thereof.
  • the antigen binding domain is a single chain variable fragment (scFv), comprising light chain CDRs CDR1, CDR2 and CDR3, and heavy chain CDRs CDR1, CDR2 and CDR3.
  • the CDRs of the anti-TALEN antibodies presented herein are numbered according to the Kabat numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the Chothia numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the contact numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the AbM numbering scheme.
  • Humanized antibodies of the anti-TALEN antibodies described herein can be prepared by known techniques.
  • a humanized monoclonal antibody comprises the variable domain of an anti-TALEN antibody (or all or part of the antigen binding site thereof) and a constant domain derived from a human antibody.
  • a humanized antibody fragment can comprise an antigen binding site of a murine or rabbit monoclonal antibody and a variable domain fragment (lacking the antigen binding site) derived from a human antibody.
  • Procedures for the production of engineered monoclonal antibodies include those described in Riechmann et al., (1988) Nature 332:323, Liu et al., (1987) Proc. Nat. Acad. Sci.
  • the chimeric antibody is a CDR grafted antibody.
  • Techniques for humanizing antibodies are discussed in, e.g., U.S. Pat. Nos. 5,869,619; 5,225,539; 5,821,337; 5,859,205; 6,881,557; Padlan et al., (1995) FASEB J. 9:133-39; Tamura et al., (2000) J. Immunol. 164:1432-41; Zhang et al., (2005) Mol. Immunol.
  • variable light and/or variable heavy chains that each have at least 70-80%, 85-90%, 90-95%, 95-97%, 97-99%, or above 99% identity to the amino acid sequences of the antigen binding domain sequences described herein.
  • the anti-idiotype antibody is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a heavy chain variable region sequence provided in Table 1a and/or a light chain variable sequence provided in Table 1b.
  • such molecules include at least one heavy chain and one light chain, whereas in other instances the variant forms contain two variable light chains and two variable heavy chains (or subparts thereof).
  • a skilled artisan will be able to determine suitable variants of the anti-TALEN antibodies as set forth herein using well-known techniques. In certain embodiments, one skilled in the art can identify suitable areas of the molecule that can be changed without destroying antigen binding activity by targeting regions not believed to be important for activity.
  • An anti-TALEN antibody of the present disclosure can also be a fully human monoclonal antibody.
  • Fully human monoclonal antibodies can be generated by any number of techniques with which those having ordinary skill in the art will be familiar. Such methods include, but are not limited to, Epstein Barr Virus (EBV) transformation of human peripheral blood cells (e.g., containing B lymphocytes), in vitro immunization of human B-cells, fusion of spleen cells from immunized transgenic mice carrying inserted human immunoglobulin genes, isolation from human immunoglobulin V region phage libraries, or other procedures as known in the art and based on the disclosure herein.
  • EBV Epstein Barr Virus
  • An anti-TALEN antibody that specifically binds to a TALEN protein and/or the FokI catalytic domain is said to be “selective” when it binds to one target more tightly than it binds to a second target.
  • An anti-TALEN antibody that specifically binds to a TALEN protein and/or the FokI catalytic domain is said to “specifically bind” its target antigen (e.g., TALEN protein and/or the FokI catalytic domain) when the dissociation constant (Kd) is in the nanomolar range (e.g., ⁇ 1 nM).
  • the antigen binding domain specifically binds antigen with “high affinity” when the Kd is 1-5 nM, and with “very high affinity” when the Kd is 0.1-0.5 nM.
  • the antigen binding domain has a Kd of ⁇ 1 nM.
  • the off-rate is ⁇ 1 ⁇ 10 ⁇ 5 .
  • the antigen binding domains will bind to TALEN proteins and molecules comprising FokI catalytic domain with a Kd of between about 1 ⁇ 10 ⁇ 7 M and 1 ⁇ 10 ⁇ 12 M, and in yet another embodiment the antigen binding domains will bind with a Kd between about 1 ⁇ 10 ⁇ 5 and 1 ⁇ 10 ⁇ 12 .
  • the anti-TALEN antibodies of the present disclosure specifically bind TALEN proteins and/or the FokI nuclease domain (e.g., SEQ ID NO: 1).
  • the anti-TALEN antibodies of the present disclosure bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1 ⁇ 10 ⁇ 6 M, less than 1 ⁇ 10 ⁇ 7 M, less than 1 ⁇ 10 ⁇ 8 M, or less than 1 ⁇ 10 ⁇ 9 M. In one particular embodiment, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1 ⁇ 10 ⁇ 7 M. In another embodiment, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1 ⁇ 10 ⁇ 8 M.
  • the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a Kd of about 1 ⁇ 10 ⁇ 7 M, about 2 ⁇ 10 ⁇ 7 M, about 3 ⁇ 10 ⁇ 7 M, about 4 ⁇ 10 ⁇ 7 M, about 5 ⁇ 10 ⁇ 7 M, about 6 ⁇ 10 ⁇ 7 M, about 7 ⁇ 10 ⁇ 7 M, about 8 ⁇ 10 ⁇ 7 M, about 9 ⁇ 10 ⁇ 7 M, about 1 ⁇ 10 ⁇ 8 M, about 2 ⁇ 10 ⁇ 8 M, about 3 ⁇ 10 ⁇ 8 M, about 4 ⁇ 10 ⁇ 8 M, about 5 ⁇ 10 ⁇ 8 M, about 6 ⁇ 10 ⁇ 8 M, about 7 ⁇ 10 ⁇ 8 M, about 8 ⁇ 10 ⁇ 8 M, about 9 ⁇ 10 ⁇ 8 M, about 1 ⁇ 10 ⁇ 9 M, about 2 ⁇ 10 ⁇ 9 M, about 3 ⁇ 10 ⁇ 9 M, about 4 ⁇ 10 ⁇ 9 M, about 5 ⁇ 10 ⁇ 9 M, about 6 ⁇ 10 ⁇ 9 M, about 7 ⁇ 10 ⁇ 9 M,
  • the Kd is calculated as the quotient of K off /K on , and the K on and K off are determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., Biacore® surface plasmon resonance technology.
  • the Kd is calculated as the quotient of K off /K on , and the K on and K off are determined using a bivalent antibody, such as a Fab fragment, as measured by, e.g., Biacore® surface plasmon resonance technology.
  • the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with an association rate (k on ) of less than 1 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ , less than 3'10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 7 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 8 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 9 ⁇ 10 ⁇ 4 M ⁇ 1 s ⁇ 1 , less than 1 ⁇ 10 ⁇ 5 M ⁇ 1 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 5 M ⁇ 1 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 5 M ⁇ 1 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 5
  • the k on can be determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • the k on is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with an dissociation rate (k off ) of less than 1 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 6 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 7 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 8 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 9 ⁇ 10 ⁇ 2 s ⁇ 1 , less than 1 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 2 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 3 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 4 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 5 ⁇ 10 ⁇ 3 s ⁇ 1 , less than 6 ⁇ 10
  • the k off is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • a monovalent antibody such as a Fab fragment
  • the k off is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain, comprising a variable heavy chain (VH), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a.
  • the VH amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH sequence presented in Table la. Kabat CDR definitions are shown in bold and Chothia CDR definitions are underlined.
  • VH Heavy Chain Variable Regions
  • Amino Acid Sequence 2299.2G3.C6 QIQLVQSGPELKKPGETVKISCKAS GYTFT DY SIH WVKQ 3 APGEGLKWMA WI NTETGA PTFADDFKG RLALSLETSANT AYLQINNLKHEDTATYFCAK EGGFYFYAMDY WGQGTSVT VSS 2299.5D4.C8 QIQLVQSGPELKKPGETVKISCKAS GYTFT DY SIH WVKQ 3 APGEGLKWMA WI NTETGA PTFADDFKG RLALSLETSANT AYLQINNLKHEDTATYFCAK EGGFYFYAMDY WGQGTSVT VSS 2299.6B3.B8.B6 QIQLVQSGPELKKPGETVKISCKAS GYAFT DY SIH WMKQ 4 APGEGLQWMG WI NTETAK P
  • anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain, comprising a variable light chain (VL), wherein the amino acid sequence or polynucleotide sequence of the VL is selected from the VL sequences presented in Table 1b.
  • VL amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL sequence presented in Table lb.
  • Kabat CDR definitions are shown in bold and Chothia CDR definitions are underlined.
  • anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain
  • anti-TALEN antibodies comprise a variable heavy chain (VH) and a variable light chain (VL), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a; and wherein the amino acid sequence or polynucleotide sequence of the VL is selected from the VL sequences presented in Table 1b.
  • the anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain comprise a VH CDR 1, CDR2, and CDR3 of a VH sequence presented in Table 1a.
  • the VH CDR 1, CDR2, and CDR3 are selected from a CDR sequence presented in Table 1c.
  • anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain comprise a VL CDR 1, CDR2, and CDR3 of a VL sequence presented in Table 1b.
  • the VH CDR 1, CDR2, and CDR3 are selected from a CDR sequence presented in Table 1d.
  • compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, computational chemistry, protein engineering, antibody structure and function, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al.
  • MOLECULAR CLONING A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 and subsequent editions; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998 and subsequent editions.
  • Transcription activator-like effector nucleases typically refer to restriction enzymes that can be engineered to cut specific sequences of DNA. They generally include a TAL effector DNA-binding domain and a DNA cleavage domain, i.e., a nuclease which cuts DNA strands. Transcription activator-like effectors (TALEs) can be engineered to bind practically any desired DNA sequence. Thus, TALENs can be introduced into cells, for use in gene editing or for genome editing in situ.
  • Non-specific DNA cleavage domain can be used in TALEN constructs including, but not limited to, wild-type FokI cleavage domain, portions of the FokI endonuclease, FokI cleavage domain variants such as those with mutations designed to improve cleavage specificity and cleavage activity.
  • a FokI domain functions as a dimer, involving two constructs with DNA binding domains for sites in a target genome with proper orientation and spacing.
  • the TALEN comprises an endonuclease (e.g., FokI) cleavage domain or cleavage half-domain.
  • the disclosed antibodies can be used for any TALEN-mediated gene editing, including targeted integration; methods and compositions for nuclease-mediated targeted integration are described in WO2015127439A1, which is incorporated by reference in its entirety.
  • Zinc finger nucleases are protein chimera comprised of a zinc finger-based DNA-binding domain and a DNA-cleavage (i.e. nuclease) domain (e.g., FokI). ZFNs are able to introduce double-strand breaks (DSB; breaks at the same or very close points in both strands of a double-stranded DNA molecule) at specific locations within a DNA molecule which can subsequently be used to disable, replace, insert or edit a targeted genomic region.
  • DSB double-strand breaks
  • Zinc fingers are among the most common DNA binding motifs found in eukaryotes. These proteins are classified according to the number and position of the cysteine and histidine residues available for zinc coordination.
  • a zinc finger consists of two antiparallel ⁇ strands, and an a helix. The zinc ion is crucial for the stability of this domain type—in the absence of the metal ion the domain unfolds as it is too small to have a hydrophobic core.
  • One very well-explored subset of zinc-fingers (the C 2 H 2 class) comprises a pair of cysteine residues in the beta strands and two histidine residues in the alpha helix which are responsible for binding a zinc ion.
  • Zinc fingers are important in regulation because when interacted with DNA and zinc ion, they provide a unique structural motif for DNA-binding proteins.
  • the structure of each individual finger is highly conserved and consists of about 30 amino acid residues, constructed as a ⁇ fold and held together by the zinc ion.
  • the ⁇ -helix occurs at the C-terminal part of the finger, while the ⁇ -sheet occurs at the N-terminal part.
  • the DNA-binding domain of a ZFN can be composed of two to eight zinc finger motifs due to their supposed modularity.
  • a ZFN comprises 2, 3, 4, 5, 6, 7, or 8 zinc finger motifs.
  • Each zinc finger motif is typically considered to recognize and bind to a three-base pair sequence and as such, a protein including more zinc fingers targets a longer sequence and therefore has a greater specificity and affinity to the target site.
  • Methods to engineer zinc finger binding domains to bind to a sequence of choice are well known in the art. See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al.
  • Zinc finger engineering methods known in the art include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, U.S. Pat.
  • the included zinc fingers can be selected via a parallel, sequential or bipartite technique or through an in vitro cell-based technique.
  • Exemplary selection methods are also known in the art, including phage display and two-hybrid systems, see, U.S. Pat. Nos. 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; and international patent publications WO 98/37186; WO 98/53057; WO 00/27878; and WO 01/88197. Enhancements of binding specificity for zinc finger binding domains have been previously described, for example, in WO 02/077227.
  • the non-specific nuclease domain of FokI is functionally independent of its natural DNA-binding domain and therefore can be employed in the construction of ZFNs. Since the domain must dimerize to accomplish a double-strand break it is necessary that a nuclease is also bound to the opposite strand by virtue of another ZFN molecule bound to its target sequence as shown in the diagram.
  • the two target sites need not be the same, so long as ZFNs targeting both sites are present. In order to form a dimer, two ZFN molecules must meet with their respective recognition sites not less than 4-6 base pairs apart but also not so far apart that they may not dimerize.
  • FokI can be employed as a homo- or a heterodimer. In some embodiments, FokI is a homodimer. In some embodiments, FokI is a heterodimer.
  • RNA-guided FokI nucleases are protein chimera comprised of a Cas9 nuclease (Cas9) DNA-binding domain and a DNA-cleavage domain (e.g., FokI-cleavage domain).
  • RFNs specifically target particular DNA sequences through the use of a guide RNA (gRNA) bearing 17-20 nucleotides of target site complementarity at the 5′ end.
  • gRNA guide RNA
  • RFNs require dimerization of the FokI DNA cleavage domain to introduce double-strand breaks (DSB; breaks at the same or very close points in both strands of a double-stranded DNA molecule) at specific locations within a DNA molecule which can subsequently be used to disable, replace, insert or edit a targeted genomic region.
  • DSB double-strand breaks
  • CRISPR-associated Cas systems have evolved in bacteria and archaea to use short RNAs to guide DNA cleavage complexes to specific nucleotide sequences.
  • the CRISPR/Cas system has been adapted for genome editing in eukaryotic cells. Cas9 unwinds DNA and checks for complementarity to the 20 base pair spacer region of the gRNA thus specifically targeting DNA sequences preceding protospacer adjacent motifs (PAM) sequences in mammalian cell genomes.
  • PAM protospacer adjacent motifs
  • the introduction of DSBs allows for target sequence alteration through one of two endogenous DNA repair mechanisms—either non-homologous end-joining (NHEJ) or homology-directed repair (HDR).
  • NHEJ non-homologous end-joining
  • HDR homology-directed repair
  • the CRISPR/Cas system has also been used for gene regulation including transcription repression and activation without altering the target sequence.
  • Targeted gene regulation based on the CRISPR/Cas system uses an enzymatically inactive Cas9 (dCas9). Additional Cas9 descriptions and gRNA requirements for programmable dCas9 are incorporated in but not limited to U.S. patent Ser. No. 14/536319, Ser. No. 14/320498, and Ser. No. 14/320467
  • TALENs, ZFNs and RFNs can bind to and cleave at targeted sites in a genome, permitting the insertion or deletion of specific DNA sequences, notably when a repair template is provided.
  • Selective cutting is achieved through sequence specific targeting by the DNA binding domain (e.g., TAL effector DNA-binding domain) and DNA cleavage by FokI nucleases.
  • the homologous recombination machinery searches for homology between the damaged chromosome and the extra-chromosomal fragment and copies the sequence of the fragment between the two broken ends of the chromosome, regardless of whether the fragment contains the original sequence, resulting in insertion of the gene of interest into the genome.
  • TALEN In addition to homology-mediated gene editing the TALEN approach can also be applied to gene editing (knock outs and insertions) mediated by non-homologous end joining.
  • the genome editing system includes 1, 2, 3, 4, 5, 6, 7, 8 or more nucleic acid construct(s) encoding a “half-TALEN” which assemble to form a complete TALEN with targeted FokI-mediated nuclease activity.
  • the genome editing system includes two or four nucleic acid constructs encoding “half-TALENs” with targeted FokI-mediated nuclease activity.
  • the nucleic acids encode dimeric TALENs, or a TALEN comprising two “half-TALENs”.
  • a genome editing system includes a polynucleotide construct bearing a donor sequence which undergoes genomic insertion after nuclease cleavage.
  • a donor sequence will have one or more homologous region(s) that share identity to a genomic sequence with which recombination is desired.
  • a donor sequence will have one or more homologous region(s) that have at least 50% sequence identity to a genomic sequence with which recombination is desired.
  • 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 99.9% sequence identity is present over a homologous region. Any value between 1% and 100% sequence identity can be present, depending upon the length of the donor polynucleotide.
  • DNA can be introduced into selected target cells in a manner such that the donor DNA is expressed, and a therapeutic product encoded thereby is produced.
  • donor DNA can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product.
  • the donor DNA encodes a therapeutic product for the treatment or prevention of disease or disorder that results from a genetically defect or deficiency.
  • the donor DNA encodes a therapeutic product for the treatment or prevention of cancer or any other disease or disorder that results from a genetic defect or deficiency.
  • the donor DNA encodes a chimeric antigen receptor (CAR).
  • CAR chimeric antigen receptor
  • viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs or RFNs to cells in vitro.
  • non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as poloxamers or liposomes.
  • the nucleic acids encoding TALENs, ZFNs or RFNs are transfected via electroporation.
  • the non-viral delivery system includes direct transfer of TALEN-, ZFN- or RFN-encoding mRNA, such as by microinjection.
  • Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Examples of viral vector delivery systems include, but are not limited to, integrase-deficient lentiviral vectors, adenoviral vectors, and vectors based on adeno-associated virus.
  • components of the genome editing system are mixed prior to administering to a subject.
  • components of the genome editing system are administered separately. Separate administration of the genome editing components can be essentially simultaneous, sequential or separated by a determined period of time.
  • Described herein are highly sensitive and reliable methods for detecting and/or measuring FokI in a sample. As shown herein, these methods can detect FokI at physiological levels.
  • Detection moieties as used herein include moieties of any structure capable of being detected by any methods known in the art.
  • a detection moiety refers to any element, molecule, functional group, compound, fragment or moiety that is detectable.
  • Detection moieties include, but are not limited to, radionuclides (e.g., 3 H, 14 C, 18 F, 19 F, 32 P, 35 S, 135 I, 125 I, 123 I, 64 Cu, 187 Re, 111 In, 90 Y, 99m Tc, 177 Lu, 89 Zr etc.), fluorescent dyes (such as, for example fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (such as, for example, acridinum esters, stabilized dioxetanes, and the like), electrochemiluminescent agents (such as, for example, Sulfo Tags), bioluminescent agents (such as, for example, luciferin), spectrally resolvable inorganic fluorescent semiconductors nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver
  • the anti-FokI antibody is associated with a detection moiety.
  • the anti-FokI antibody can be covalently or non-covalently associated with the detection moiety.
  • the detection moiety is selected from sulfo-tag, horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin.
  • the detection moiety is an electrochemiluminescent (ECL) label.
  • ECL-based assays involve the use of electrochemiluminescent compounds as labels (referred to herein as ECL labels). Any compounds capable of electrochemiluminescence can be used as an ECL labels.
  • ECL labels include, but are not limited to, organometallic compounds such as the tris-bipyridyl-ruthenium (RuBpy) moiety where the metal is from, for example, the metals of group VII and VIII, including Re, Ru, Ir and Os.
  • the ECL label is a Sulfo-Tag label.
  • ECL coreactants Species that react with the ECL label in the ECL process are referred to herein as ECL coreactants.
  • ECL coreactants include tertiary amines (e.g. tripropylamine (TPA)), oxalate, and persulfate.
  • TPA tripropylamine
  • the anti-TALEN antibody is associated with a detection moiety.
  • the detection moiety can be associated with the anti-TALEN antibody through covalent conjugation or through non-covalent association. Covalent conjugation of the detection moiety to the anti-TALEN antibody can be direct or can be through a linker.
  • the detection moiety is selected from an ECL tag (e.g., Sulfo-Tag), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin.
  • detecting the presence or absence of a FokI comprising molecule comprises measurement of electrochemiluminescence, luminescence, fluorescence, or absorbance by any means known in the art.
  • the detecting step can involve a quantitative measurement, which can be used to determine the amount of FokI polypeptide in the sample.
  • Measurement(s) to determine the presence or intensity of FokI can be performed by a hand method or can be carried out using an apparatus such as an analyzer.
  • the detection moiety can produce a color output.
  • Methods can include visual appearance of a colored product and/or an instrument such as an analyzer can be used to detect or quantify the color product.
  • the detecting step comprises a measurement of electrochemiluminescence, which can be performed using a commercially available instrument.
  • the detection moiety is a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, or a hapten.
  • the detectable label is a fluorescent label is selected from the group consisting of an Atto dye, an Alexa Fluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, D
  • FokI is a bacterial type IIS restriction endonuclease that is naturally found in Flavobacterium okeanokoites .
  • Natural FokI consists of an N-terminal DNA-binding domain and a non-specific DNA cleavage domain at the C-terminus. (UniProt Accession Number P14870)
  • the full length wild type FokI amino acid sequence is:
  • the FokI DNA cleavage domain can function independently of the DNA binding domain.
  • a FokI polypeptide consists, consists essentially of or comprises the FokI nuclease domain.
  • the FokI catalytic domain polypeptide is wild-type amino acids 439-583 of SEQ ID NO: 2.
  • the anti-TALEN antibodies described herein bind to a molecule comprising SEQ ID NO:1.
  • the FokI protein is modified.
  • the modified FokI protein includes an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to wild-type FokI catalytic domain (SEQ ID NO:1).
  • the FokI protein comprises biologically active fragments of FokI.
  • the biologically active fragment includes the catalytic domain of FokI.
  • FokI protein includes the DNA-cleavage domain of FokI.
  • the FokI protein comprises an amino acid sequences that differs from SEQ ID NO: 1 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or more amino acids.
  • Sample types of the present disclosure include any materials that have, are suspected to have, are likely to have, or are confirmed to have TALEN proteins or molecules comprising a FokI catalytic domain.
  • the sample is an in vitro sample.
  • the sample is an in vivo sample.
  • the sample is of biological origin (e.g., a biological sample).
  • Biological samples include all materials that at one time were part of a living organism.
  • the biological sample is from a mammal. Mammals include, but are not limited to, humans, dogs, cats, cows, pigs, sheep, non-human primates and llamas. Humans can be of any age.
  • the biological sample can take any form and include, but are not limited to, cells, tissue, whole blood, plasma, serum, urine, stool, saliva, cord blood, sperm, aqueous or vitreous humor, chorionic villus sample, and combination thereof.
  • the sample is a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.
  • a sample e.g., a serum sample is to be analyzed for the presence (or absence) or level of TALEN or FokI protein.
  • kits for use in detecting and/or measuring FokI in a sample typically comprise one or more substances, reagents and/or materials for use in the methods provided herein.
  • the kit can include instructions for performing such methods.
  • Kits for detecting and/or measuring FokI can include various reagents necessary for the analyzing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000 or more samples.
  • the kit can allow for the simultaneous or near simultaneous analysis of a plurality of samples, such as a microplate-type assay kit.
  • the kit can be disposable, such that reagents and materials are intended for a single use and/or to be disposed of after performance of the assay.
  • a kit for use in detecting and/or measuring FokI in a sample comprises an anti-TALEN antibody described herein and optionally conjugated to a detection moiety, or can comprise materials allowing a used of the kit to perform such a conjugation.
  • Substrates of the FokI detection kits described herein can take any suitable form that permits the association of anti-FokI antibodies described herein and FokI containing complexes.
  • the substrate is contained in or part of a microplate. Any suitable detection moiety known in the art can be used.
  • detection moieties include, but are not limited to, an ECL tag (e.g., Sulfo-Tag), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin.
  • ECL tag e.g., Sulfo-Tag
  • horseradish peroxidase e.g., Sulfo-Tag
  • horseradish peroxidase alkaline phosphatase
  • FITC digoxigenin
  • acridan digoxigenin
  • RPE digoxigenin
  • luciferin luciferin
  • fluorophores chromophores
  • radioisotopes or biotin.
  • any suitable methods of detection can be used in conjunction with FokI detection kits described herein.
  • the kit may or may not include reagents, materials and or instruments for performing the detection
  • kits may or may not include instructions for a specific detection method.
  • a kit can refer a user to standard methods of detection.
  • the kit can refer a user to follow instructions associated with other instrumentation for detection.
  • methods and kits of the present disclosure can be used for the evaluation and/or monitoring of cellular or gene therapy, such as CAR T therapy.
  • the cellular or gene therapy is a ZFN-based gene therapy.
  • the cellular or gene therapy is a RFN-based gene therapy.
  • the cellular therapy is a TALEN-based gene therapy.
  • the cellular or gene therapy comprises the administration of a DNA construct.
  • the cellular or gene therapy comprises mRNA replacement therapy.
  • the cellular or gene therapy comprises cellular replacement therapy, such as Chimeric Antigen Receptor (CAR)-based therapy, which can comprise allogeneic or autologous cellular replacement.
  • CAR Chimeric Antigen Receptor
  • Cellular replacement therapy can comprise administering cells that have been transduced or transfected with a nucleic acid construct encoding a FokI protein or a biologically active fragment thereof.
  • samples for evaluating and/or monitoring cellular or gene therapy can be obtained prior to the initiation of therapy.
  • samples are obtained after a first cellular or gene therapy treatment or dose.
  • samples are obtained after the conclusion of gene therapy.
  • samples are obtained at specific time points, intervals, or any other metric of time before, during or after cellular or gene therapy is performed.
  • FokI detection is used for assessing potential for cellular or gene therapy.
  • the anti-TALEN antibodies of the present disclosure can be used for the evaluation and/or monitoring of gene therapy or cellular replacement therapy, such as CAR therapy.
  • the gene therapy comprises administering to a patient a population of cells engineered with a TALEN protein to express a chimeric antigen receptor (CAR).
  • the CAR containing immune cells can be used to treat malignancies involving aberrant expression of biomarkers, including cancer.
  • CAR containing immune cells of the disclosure can be used to treat non-Hodgkins lymphoma such as diffuse large B-cell lymphoma (DLBCL), leukemia (e.g., CLL or ALL), multiple myeloma (MM), small cell lung cancer, melanoma, low grade gliomas, glioblastoma, medullary thyroid cancer, carcinoids, dispersed neuroendocrine tumors in the pancreas, bladder and prostate, testicular cancer, and lung adenocarcinomas with neuroendocrine features.
  • DLBCL diffuse large B-cell lymphoma
  • MM multiple myeloma
  • small cell lung cancer melanoma
  • low grade gliomas glioblastoma
  • medullary thyroid cancer carcinoids
  • dispersed neuroendocrine tumors in the pancreas, bladder and prostate testicular cancer
  • lung adenocarcinomas with neuroendocrine features can be used to treat non-
  • cancer includes, but is not limited to, solid tumors and blood-born tumors.
  • cancer refers to disease of skin tissues, organs, blood, and vessels, including, but not limited to, cancers of the bladder, bone or blood, brain, breast, cervix, chest, colon, endometrium, esophagus, eye, head, kidney, liver, lymph nodes, lung, mouth, neck, ovaries, pancreas, prostate, rectum, stomach, testis, throat, and uterus.
  • Specific cancers include, but are not limited to, advanced malignancy, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastases, glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, recurrent malignant giolma, anaplastic astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C & D colorectal cancer, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karotype acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), cutaneous T-Cell lymphoma, cutaneous B-Cell lymphoma, diffuse large B-Cell lymph
  • the cancer is metastatic.
  • the cancer is refractory or resistant to chemotherapy or radiation.
  • a cancer has been reduced by a degree determined to be less than desire and a re-treatment is determined to be appropriate.
  • Antibodies obtained from fusion #2296 resulted in over 30 ELISA positives screened on FokI and full-length TALEN protein. These antibodies were negative on His-tag antigen.
  • Biacore® analysis of fusion #2296 antibodies resulted in kD values ranging from 5 nM to 100 nM.
  • the Biacore® kinetics of fusion #2296 REVIMS Day 12 are shown in Table 2 below.
  • Hybridoma fusion #2299 cells were obtained from a long immunization on day 94. Balb/c mouse #2299 with higher antibody titer was selected for fusion. Antibodies obtained from fusion #2299 resulted in over 68 ELISA positives screened on FokI and full-length TALEN protein. These antibodies were negative on the His tag antigen. Biacore® analysis of fusion #2299 antibodies resulted in kD values ranging from sub nM to 100 nM. Five out of the top 12 ELISA binders were positive in Western Blot analysis with supernatant ( FIG. 1 ). The Biacore® kinetics of exemplary antibodies from fusion #2299 are shown in Table 3 below.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present disclosure provides, among other things, antibodies for detecting TALENs and/or FokI nucleases in a sample and methods of using the same.

Description

    CROSS REFERENCE
  • This application is a divisional of U.S. application Ser. No. 16/900,602, filed Jun. 12, 2020, which claims the benefit of priority to U.S. Provisional Application No. 62/861,214, filed on Jun. 13, 2019, the content of both of which is hereby incorporated by reference in its entirety.
    • SEQUENCE LISTING
  • This application is being filed electronically via Patent Center and includes an electronically submitted sequence listing in .xml format. The .xml file contains a sequence listing entitled “AT-021_03_SL.xml” created on Jul. 17, 2023, and having a size of 38,698 bytes. The sequence listing contained in this .xml file is part of the specification and is incorporated herein by reference in its entirety.
    • TECHNICAL FIELD
  • The present disclosure relates to antigen binding molecules, including, but not limited to, antibodies, which specifically bind gene editing proteins (e.g., TALEN proteins comprising a FokI, also referred to as Fok-1 or Fok1, catalytic domain) and polynucleotides encoding the same, and methods of use.
    • BACKGROUND
  • Genome editing tools such as Transcription activator-like effector nucleases (TALEN®), Zinc-finger nucleases (ZFNs), and RNA-guided FokI Nucleases (RFNs) are powerful tools that enable the precise revision, insertion or deletion of genes. TALENs, ZFNs, and RFNs can bind to and cleave at targeted sites in a genome. The resulting cleaved DNA is repaired via the endogenous cell DNA repair mechanism of non-homologous end joining (NHEJ), or via homology-directed repair (HDR) when a repair template is provided. TALENs use a TAL effector DNA-binding domain fused to a DNA cleavage domain (e.g., FokI). ZFNs are composed of a restriction endonuclease cleavage or catalytic domain, such as FokI, linked to engineered Cys2His2 zinc-finger, DNA-binding polypeptides. RFNs are composed of a FokI nuclease fused to catalytically inactive form of Cas9. For efficient genome editing in mammals (e.g., humans, dogs, cattle, non-human primates, etc.), it is envisioned that TALENs, ZFNs and RFNs will be expressed at high level. Due to the risk of sustained nuclease activity and off-target effects, as well as potential immunogenicity, there is a need in the art for antibodies that recognize genome editing tools (e.g., anti-TALEN and/or anti-FokI antibodies) capable of binding nuclease proteins in order to evaluate the safety and efficacy of various gene editing therapies.
    • SUMMARY OF THE INVENTION
  • The present disclosure provides, among other things, antibodies for the detection of FokI catalytic domains and full-length TALEN proteins in a sample. As described herein, including in the Examples below, the present disclosure provides anti-TALEN antibodies which specifically bind TALEN and FokI proteins. In some embodiments anti-TALEN antibodies of the present disclosure can be used to evaluate gene editing therapies and processes.
  • In one aspect, the instant disclosure provides an anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO: 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO: 7. In one embodiment the anti-TALEN antibody is humanized. In various embodiments, the antibody is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.
  • In specific embodiments, the antibody comprises a variable heavy chain (HC) selected from the group consisting of SEQ ID NOs: 3-6, and in further embodiments the anti-TALEN antibody comprises a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 12-14, and/or a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 15-20, and/or a heavy chain CDR3 comprising SEQ ID NO: 21. In specific embodiments, an anti-TALEN antibody comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table 1c. Also provided is an anti-TALEN antibody comprising a VH amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule provided herein.
  • In other embodiments an anti-TALEN antibody comprises a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11. In specific embodiments, an anti-TALEN antibody comprises a light chain CDR1 comprising SEQ ID NO: 22, and/or a light chain CDR2 selected from the group consisting of SEQ ID NO: 23-25, and/or a light chain CDR3 selected from the group consisting of SEQ ID NOs: 26-28. Further provided is an anti-TALEN antibody wherein the light chain comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, each CDR comprising an amino acid sequence in Table ld. Also provided is an anti-TALEN antibody, comprising a VL amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL of an antigen binding molecule provided herein.
  • In another embodiment, provided herein is an anti-TALEN antibody, comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d)a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26 and in a further embodiment, an anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 7.
  • In another embodiment provided herein is an anti-TALEN antibody, comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment an anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 8.
  • In a further embodiment, provided herein is an anti-TALEN antibody comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26, and in a further embodiment the anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 9.
  • In still a further embodiment, provided herein is an anti-TALEN antibody
  • comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28, and in a further embodiment the anti-TALEN antibody comprises (a) a VH comprising the amino acid sequence of SEQ ID NO: 5; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 10.
  • Also provided is an anti-TALEN antibody, comprising (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17; (c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21; (d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22; (e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and (f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27, and in a further embodiment the anti-TALEN antibody of claim 23, comprising (a) a VH comprising the amino acid sequence of SEQ ID NO: 6; and (b) a VL comprising the amino acid sequence of SEQ ID NO: 11.
  • In various embodiments the anti-TALEN antibody further comprises a detectable label, and in some embodiments the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten. When the detectable label is a fluorescent label, the fluorescent label can be selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP,Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry. In specific embodiments the fluorescent label is R-Phycoerythrin (PE) or Allophycocyanin (APC)
  • Also provided is a composition comprising an anti-TALEN antibody provided herein and an acceptable carrier or vehicle, e.g., a pharmaceutically acceptable carrier or vehicle.
  • Polynucleotides encoding the heavy chain of an anti-TALEN antibody disclosed herein are also provided. Polynucleotide encoding the light chain of an anti-TALEN antibody disclosed herein are also provided. Vectors comprising one or both of the heavy and light chain encoding polynucleotides are also provided. Further, a cell comprising one or both of the vectors is provided, and the cell can comprise a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell. A method of making an anti-TALEN antibody disclosed herein is provided and comprises incubating a cell comprising one or both of the vectors described above under suitable conditions.
  • In yet a further embodiment a method of determining the presence or
  • absence of a TALEN protein in a sample is provided and in one embodiment comprises contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample; in some embodiments the anti-TALEN antibody comprises an antibody provided herein, or a humanized form thereof. Additionally, the sample can be a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.
  • Various aspects of the present disclosure are described in detail in the following sections. The use of sections is not meant to limit the present disclosure. Each section can apply to any aspect of the present disclosure. In this application, the use of “or” means “and/or” unless stated otherwise. All references cited herein are incorporated by reference in their entirety. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the present disclosure belongs.
    • BRIEF DESCRIPTION OF THE DRAWINGS
  • The drawings provided in the present disclosure are for illustration purposes only and not for limitation.
  • FIG. 1 depicts a Western blot analysis of hybridoma supernatants from fusion #2299 (Numbers 13-16 noted in the figure) and #2296 ( Numbers 3, 6, 7, 8, and 11 noted in the figure).
    •  DEFINITIONS
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art (e.g., in the arts of genetic engineering, cell culture, molecular genetics, nucleic acid chemistry and biochemistry).
  • In order for the present disclosure to be more readily understood, certain terms are first defined below. Additional definitions for the following terms and other terms are set forth throughout the present disclosure.
  • Affinity: As is known in the art, “affinity” refers to a measure of the tightness that a particular ligand binds to its partner. Affinities can be measured in different ways. In some embodiments, affinity is measured by a quantitative assay. In some embodiments, binding partner concentration and/or ligand concentration can be varied. In some such embodiments, affinity can be compared to a reference under comparable conditions (e.g., concentrations).
  • Amino acid: in its broadest sense, refers to any compound and/or substance that can be incorporated into a polypeptide chain, e.g., through formation of one or more peptide bonds. In some embodiments, an amino acid has the general structure H2N—C(H)(R)—COOH. In some embodiments, an amino acid is a naturally-occurring amino acid. In some embodiments, an amino acid is a synthetic amino acid; in some embodiments, an amino acid is a D-amino acid; in some embodiments, an amino acid is an L-amino acid. The term “standard amino acid” refers to any of the twenty standard L-amino acids commonly found in naturally occurring peptides. The term “nonstandard amino acid” refers to any amino acid, other than the standard amino acids, regardless of whether it is prepared synthetically or obtained from a natural source. In some embodiments, an amino acid, including a carboxy- and/or amino-terminal amino acid in a polypeptide, can contain a structural modification as compared with the general structure above. For example, in some embodiments, an amino acid can be modified by methylation, amidation, acetylation, and/or substitution as compared with the general structure. As will be clear from context, in some embodiments, the term “amino acid” is used to refer to a free amino acid; in some embodiments it is used to refer to an amino acid residue of a polypeptide.
  • Antibody: As used herein, the term “antibody” refers to a species of antigen binding proteins comprising a polypeptide that includes canonical immunoglobulin sequence elements sufficient to confer specific binding to a particular target antigen. As is known in the art, intact antibodies as produced in nature are approximately 150 kD tetrameric agents comprised of two identical heavy chain polypeptides (about 50 kD each) and two identical light chain polypeptides (about 25 kD each) that associate with each other into what is commonly referred to as a “Y-shaped” structure. Each heavy chain is comprised of at least four domains (each about 110 amino acids long), an amino-terminal variable (VH) domain (located at the tips of the Y structure), followed by three constant domains: CH1, CH2, and the carboxy-terminal CH3 (located at the base of the Y′s stem). A short region, commonly referred to as the “switch”, connects the heavy chain variable and constant regions. The “hinge” connects CH2 and CH3 domains to the rest of the antibody.
  • Two disulfide bonds in this hinge region connect the two heavy chain polypeptides to one another in an intact antibody. Each light chain is comprised of two domains—an amino-terminal variable (VL) domain, followed by a carboxy-terminal constant (CL) domain, separated from one another by another “switch”. Intact antibody tetramers are comprised of two heavy chain-light chain dimers in which the heavy and light chains are linked to one another by a single disulfide bond; two other disulfide bonds connect the heavy chain hinge regions to one another, so that the dimers are connected to one another and the tetramer is formed. Naturally-produced antibodies are also glycosylated, typically on the CH2 domain. Each domain in a natural antibody has a structure characterized by an “immunoglobulin fold” formed from two beta sheets (e.g., 3-, 4-, or 5-stranded sheets) packed against each other in a compressed antiparallel beta barrel. Each variable domain contains three hypervariable loops known as “complement determining regions” (CDR1, CDR2, and CDR3) and four somewhat invariant “framework” regions (FR1, FR2, FR3, and FR4). When natural antibodies fold, the FR regions form the beta sheets that provide the structural framework for the domains, and the CDR loop regions from both the heavy and light chains are brought together in three-dimensional space so that they create a single hypervariable antigen binding site located at the tip of the Y structure. The Fc region of naturally-occurring antibodies binds to elements of the complement system, and also to receptors on effector cells, including for example effector cells that mediate cytotoxicity. In some embodiments, an antibody is polyclonal; in some embodiments, an antibody is monoclonal.
  • Binding: It will be understood that the term “binding”, as used herein, typically refers to a non-covalent association between or among two or more entities. “Direct” binding involves physical contact between entities or moieties; “indirect” binding involves physical interaction by way of physical contact with one or more intermediate entities.
  • Chromosome: As used herein, the term “chromosome” refers to a linear molecule of DNA with associated proteins in the nucleus of eukaryotic cells that carries the genes and functions in the transmission of hereditary information.
  • Corresponding to: as used herein designates the position/identity of an amino acid residue in a polypeptide of interest. Those of ordinary skill will appreciate that, for purposes of simplicity, residues in a polypeptide are often designated using a canonical numbering system based on a reference related polypeptide, so that an amino acid “corresponding to” a residue at position 190, for example, need not actually be the 190th amino acid in a particular amino acid chain but rather corresponds to the residue found at 190 in the reference polypeptide; those of ordinary skill in the art readily appreciate how to identify “corresponding” amino acids.
  • Detection moiety: The term “detection moiety” as used herein refers to any element, molecule, functional group, compound, fragment or moiety that is detectable. In some embodiments, a detection moiety is provided or utilized alone. In some embodiments, a detection moiety is provided and/or utilized in association with (e.g., joined to) another agent. Examples of detection moieties include, but are not limited to: various ligands, radionuclides (e.g., 3H, 14C, 18F, 19F, 32P, 35S, 135I, 125I, 123I, 64Cu, 187Re, 111In, 90Y, 99mTc, 177Lu, 89Zr etc.), fluorescent dyes (such as, for example fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (such as, for example, acridinum esters, stabilized dioxetanes, and the like), electrochemiluminescent agents (such as, for example, Sulfo Tags), bioluminescent agents (such as, for example, luciferin), spectrally resolvable inorganic fluorescent semiconductors nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, platinum, etc.), nanoclusters, paramagnetic metal ions, enzymes (such as, for example, horseradish peroxidase, alkaline phosphatase, etc.), colorimetric labels (such as, for example, dyes, colloidal gold, and the like), biotin, digoxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available.
  • Engineered: In general, the term “engineered” refers to the aspect of having been manipulated by the hand of man. For example, a polynucleotide is considered to be “engineered” when two or more sequences that are not linked together in that order in nature are manipulated by the hand of man to be directly linked to one another in the engineered polynucleotide. For example, in some embodiments of the present disclosure, an engineered polynucleotide can comprise a regulatory sequence that is found in nature in operative association with a first coding sequence but not in operative association with a second coding sequence, is linked by the hand of man so that it is operatively associated with the second coding sequence. Comparably, a cell or organism is considered to be “engineered” if it has been manipulated so that its genetic information is altered (e.g., new genetic material not previously present has been introduced, for example by transformation, mating, somatic hybridization, transfection, transduction, or other mechanism, or previously present genetic material is altered or removed, for example by substitution or by a deletion mutation, or by mating protocols). As is common practice and is understood by those in the art, progeny of an engineered polynucleotide or cell are typically still referred to as “engineered” even though the actual manipulation was performed on a prior entity.
  • Expression: As used herein, “expression” of a nucleic acid sequence refers to one or more of the following events: (1) production of an RNA template from a DNA sequence (e.g., by transcription); (2) processing of an RNA transcript (e.g., by splicing, editing, 5′ cap formation, and/or 3′ end formation); (3) translation of an RNA into a polypeptide or protein; and/or (4) post-translational modification of a polypeptide or protein.
  • FokI: As used herein, the term “FokI” (alternatively referred to as Fok1 or Fok-1) refers to a bacterial type IIS restriction endonuclease that is naturally found in Flavobacterium okeanokoites. Natural FokI comprises of an N-terminal DNA-binding domain and a non-specific DNA cleavage domain at the C-terminus. The FokI DNA cleavage domain can function independently of the DNA binding domain. As used herein, FokI refers to a protein or a nucleic acid encoding a protein that comprises the DNA cleavage domain (i.e., the nuclease domain) of FokI. FokI can refer to the entire FokI protein (SEQ ID NO: 2) or just the catalytic nuclease domain (SEQ ID NO: 1). The term “FokI” refers to all fragments and variants of FokI including mutants, derivatives, analogs, truncations, fusion constructs, and multimers of FokI, including FokI dimers. In some embodiments, FokI is recombinantly produced. In some embodiments, a FokI polypeptide is conjugated to or tagged with an additional moiety, such as a binding moiety and/or a detection moiety. As will be clear from context, in some embodiments, the term “FokI” is used to refer to the FokI polypeptide or fragments or variants thereof in some embodiments “FokI” is used to refer to nucleic acids encoding a FokI polypeptide and fragments and variants thereof.
  • Fragment: A “fragment” of a biological molecule as described herein has a structure that includes a discrete portion of the whole but lacks one or more moieties found in the whole (e.g., a polypeptide lacking one or more amino acids). In some embodiments, a fragment consists of such a discrete portion. In some embodiments, a fragment consists of or comprises a characteristic structural element or moiety found in the whole (e.g. a polypeptide domain). In some embodiments, the biological molecule is a polymer (e.g. a nucleic acid polymer or a polypeptide). In some embodiments, a polymer fragment comprises or consists of at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500 or more monomeric units (e.g., residues) as found in the whole polymer. In some embodiments, a polymer fragment comprises or consists of at least about 5%, 10%, 15%, 20%, 25%, 30%, 25%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of the monomeric units (e.g., residues) found in the whole polymer. In some embodiments, the whole biological molecule can be referred to as the “parent” of the whole.
  • Fusion: A “fusion molecule” is a molecule in which two or more subunit molecules are linked, preferably covalently. The subunit molecules can be the same chemical type of molecule or can be different chemical types of molecules. Examples fusions of the same chemical type of molecule include, but are not limited to, fusion proteins (for example, a fusion between a Zinc Finger Protein or TALEN DNA-binding domain to a FokI cleavage domain) and fusion nucleic acids (for example, a nucleic acid encoding the fusion protein described supra). Examples fusions of different chemical types of molecule include, but are not limited to, nucleic acid-polypeptide fusions (for example, a fusion between an RNA molecule and a FokI cleavage domain).
  • Gene: As used herein, the term “gene” refers to a DNA sequence that codes for a product (e.g., an RNA product and/or a polypeptide product). In some embodiments, a gene includes coding sequence (i.e., sequence that encodes a particular product); in some embodiments, a gene includes non-coding sequence. In some particular embodiments, a gene can include both coding (e.g., exonic) and non-coding (e.g., intronic) sequence. In some embodiments, a gene can include one or more regulatory elements that, for example, can control or impact one or more aspects of gene expression (e.g., cell-type-specific expression, inducible expression, etc).
  • Gene or Cell therapy: As used herein, the term “gene or cell therapy” refers to insertion or deletion of specific genomic DNA sequences to treat or prevent a disorder or condition for which such therapy is sought. In some embodiments, the insertion or deletion of genomic DNA sequences occurs in specific cells (i.e. target cells). Target cells can be from a mammal and/or can be cells in a mammalian subject. Mammals include but are not limited to humans, dogs, cats, cows, sheep, pigs, llamas, non-human primates, etc. In some embodiments, heterologous DNA is transferred to target cells. The heterologous DNA can be introduced into the selected target cells in a manner such that the heterologous DNA is expressed, and a therapeutic product encoded thereby is produced. Additionally, or alternatively, the heterologous DNA can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. Genetic or cell therapy can also be used to deliver nucleic acid encoding a gene product that replaces a defective gene or supplements a gene product produced by the mammal or the cell in which it is introduced. The heterologous DNA encoding the therapeutic product can be modified prior to introduction into the cells of the afflicted subject in order to enhance or otherwise alter the product or expression thereof. Genetic or cell therapy can also involve delivery of an inhibitor or repressor or other modulator of gene expression. Gene therapy can include in vivo or ex vivo techniques. In some embodiments, gene or cell therapy includes administering nucleic acids encoding Transcription activator-like effector nucleases (TALENs), Zinc-Finger Nucleases (ZFNs) or RNA-guided FokI nucleases (RFNs). In some embodiments, viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs or RFNs to cells in vitro. Non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as poloxamers or liposomes. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. For a review of gene therapy procedures, see, e.g., Anderson, Science 256:808-813 (1992); Miller, Nature 357:455-460 (1992); Feuerbach et al., Kidney International 49:1791-1794 (1996); Urnov et al., Nature Reviews Genetics 11, 636-646 (2010); and Collins et al., Proceedings Biologicial Sciences/The Royal Society, 282(1821):pii 20143003 (2015).
  • Genome: As used herein, the term “genome” refers to the total genetic information carried by an individual organism or cell, represented by the complete DNA sequences of its chromosomes.
  • High affinity binding: The term “high affinity binding”, as used herein refers to a high degree of tightness with which a particular ligand binds to its partner. Affinities can be measured by any available method, including those known in the art. In some embodiments, binding is considered to be high affinity if the Kd is about 500 pM or less (e.g., below about 400 pM, about 300 pM, about 200 pM, about 100 pM, about 90 pM, about 80 pM, about 70 pM, about 60 pM, about 50 pM, about 40 pM, about 30 pM, about pM, about 10 pM, about 5 pM, about 4 pM, about 3 pM, about 2 pM, etc.) in binding assays. In some embodiments, binding is considered to be high affinity if the affinity is stronger (e.g., the Kd is lower) for a polypeptide of interest than for a selected reference polypeptide. In some embodiments, binding is considered to be high affinity if the ratio of the Kd for a polypeptide of interest to the Kd for a selected reference polypeptide is 1:1 or less (e.g., 0.9:1, 0.8:1, 0.7:1, 0.6:1, 0.5:1. 0.4:1, 0.3:1, 0.2:1, 0.1:1, 0.05:1, 0.01:1, or less). In some embodiments, binding is considered to be high affinity if the Kd for a polypeptide of interest is about 100% or less (e.g., about 99%, about 98%, about 97%, about 96%, about 95%, about 90%, about 85%, about 80%, about 75%, about 70%, about 65%, about 60%, about 55%, about 50%, about 45%, about 40%, about 35%, about 30%, about 25%, about 20%, about 15%, about 10%, about 5%, about 4%, about 3%, about 2%, about 1% or less) of the Kd for a selected reference polypeptide.
  • Homology: As used herein, the term “homology” refers to the overall relatedness between polymeric molecules, e.g., between nucleic acid molecules (e.g., DNA molecules and/or RNA molecules) and/or between polypeptide molecules. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical. In some embodiments, polymeric molecules are considered to be “homologous” to one another if their sequences are at least 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% similar.
  • In vitro: The term “in vitro” as used herein refers to events that occur in an artificial environment, e.g., in a test tube or reaction vessel, in cell culture, etc., rather than within a multi-cellular organism.
  • In vivo: as used herein refers to events that occur within a multi-cellular organism, such as a human and a non-human animal. In the context of cell-based systems, the term can be used to refer to events that occur within a living cell (as opposed to, for example, in vitro systems).
  • Isolated: as used herein, refers to a substance and/or entity that has been (1) separated from at least some of the components with which it was associated when initially produced (whether in nature and/or in an experimental setting), and/or (2) designed, produced, prepared, and/or manufactured by the hand of man. Isolated substances and/or entities can be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of the other components with which they were initially associated. In some embodiments, isolated agents are about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% pure. As used herein, a substance is “pure” if it is substantially free of other components. In some embodiments, as will be understood by those skilled in the art, a substance can still be considered “isolated” or even “pure”, after having been combined with certain other components such as, for example, one or more carriers or excipients (e.g., buffer, solvent, water, etc.); in such embodiments, percent isolation or purity of the substance is calculated without including such carriers or excipients. To give but one example, in some embodiments, a biological polymer such as a polypeptide or polynucleotide that occurs in nature is considered to be “isolated” when, a) by virtue of its origin or source of derivation is not associated with some or all of the components that accompany it in its native state in nature; b) it is substantially free of other polypeptides or nucleic acids of the same species from the species that produces it in nature; c) is expressed by or is otherwise in association with components from a cell or other expression system that is not of the species that produces it in nature. Thus, for instance, in some embodiments, a polypeptide that is chemically synthesized or is synthesized in a cellular system different from that which produces it in nature is considered to be an “isolated” polypeptide. Alternatively or additionally, in some embodiments, a polypeptide that has been subjected to one or more purification techniques can be considered to be an “isolated” polypeptide to the extent that it has been separated from other components a) with which it is associated in nature; and/or b) with which it was associated when initially produced.
  • Linker: as used herein, is used to refer to that portion of a multi-element polypeptide that connects different elements to one another. For example, those of ordinary skill in the art appreciate that a polypeptide whose structure includes two or more functional or organizational domains often includes a stretch of amino acids between such domains that links them to one another. In some embodiments, a polypeptide comprising a linker element has an overall structure of the general form S1-L-S2, wherein S1 and S2 can be the same or different and represent two domains associated with one another by the linker. In some embodiments, a linker is at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100 or more amino acids in length. In some embodiments, a linker is characterized in that it tends not to adopt a rigid three-dimensional structure, but rather provides flexibility to the polypeptide. A variety of different linker elements that can appropriately be used when engineering polypeptides (e.g., fusion polypeptides) known in the art (see e.g., Holliger, P., et al. (1993) Proc. Natl. Acad. Sci. USA 90:6444-6448; Poljak, R. J., et al. (1994) Structure 2: 1 121-1123).
  • Nucleic acid: as used herein, in its broadest sense, the term “nucleic acid” refers to any compound and/or substance that is or can be incorporated into an oligonucleotide chain. In some embodiments, a nucleic acid is a compound and/or substance that is or can be incorporated into an oligonucleotide chain via a phosphodiester linkage. As will be clear from context, in some embodiments, “nucleic acid” refers to individual nucleic acid residues (e.g., nucleotides and/or nucleosides); in some embodiments, “nucleic acid” refers to an oligonucleotide chain comprising individual nucleic acid residues. In some embodiments, a “nucleic acid” is or comprises RNA; in some embodiments, a “nucleic acid” is or comprises DNA. In some embodiments, a nucleic acid is, comprises, or consists of one or more natural nucleic acid residues. In some embodiments, a nucleic acid is, comprises, or consists of one or more nucleic acid analogs. In some embodiments, a nucleic acid has a nucleotide sequence that encodes a functional gene product such as an RNA or protein. In some embodiments, a nucleic acid includes one or more introns. In some embodiments, nucleic acids are prepared by one or more of isolation from a natural source, enzymatic synthesis by polymerization based on a complementary template (in vivo or in vitro), reproduction in a recombinant cell or system, and chemical synthesis. In some embodiments, a nucleic acid is at least 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 225, 250, 275, 300, 325, 350, 375, 400, 425, 450, 475, 500, 600, 700, 800, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000 or more residues long. In some embodiments, a nucleic acid is single stranded; in some embodiments, a nucleic acid is double stranded. In some embodiments a nucleic acid has a nucleotide sequence comprising at least one element that encodes, or is the complement of a sequence that encodes, a polypeptide. In some embodiments, a nucleic acid has enzymatic activity.
  • Physiological conditions: as used herein, has its art-understood meaning referencing conditions under which cells or organisms live and/or reproduce. In some embodiments, the term refers to conditions of the external or internal milieu that can occur in nature for an organism or cell system. In some embodiments, physiological conditions are those conditions present within the body of a human or non-human animal, especially those conditions present at and/or within a surgical site. Physiological conditions typically include, e.g., a temperature range of about 20-about 40° C., atmospheric pressure of about 1, pH of about 6-about8, glucose concentration of about 1-about 20 mM, oxygen concentration at atmospheric levels, and gravity as it is encountered on earth. In some embodiments, conditions in a laboratory are manipulated and/or maintained at physiologic conditions. In some embodiments, physiological conditions are encountered in an organism.
  • Polypeptide: The term “polypeptide”, as used herein, generally has its art-recognized meaning of a polymer of at least three amino acids. Those of ordinary skill in the art will appreciate that the term “polypeptide” is intended to be sufficiently general as to encompass not only polypeptides having a complete sequence recited herein, but also to encompass polypeptides that represent functional fragments (i.e., fragments retaining at least one activity) of such complete polypeptides. Moreover, those of ordinary skill in the art understand that protein sequences generally tolerate some substitution without destroying activity. Thus, any polypeptide that retains activity and shares at least about 30-40% overall sequence identity, often greater than about 50%, 60%, 70%, or 80%, and further usually including at least one region of much higher identity, often greater than 90% or even 95%, 96%, 97%, 98%, or 99% in one or more highly conserved regions, usually encompassing at least 3-4 and often up to 20 or more amino acids, with another polypeptide of the same class, is encompassed within the relevant term “polypeptide” as used herein. Polypeptides can contain L-amino acids, D-amino acids, or both and can contain any of a variety of amino acid modifications or analogs known in the art. Useful modifications include, e.g., terminal acetylation, amidation, methylation, etc. In some embodiments, proteins can comprise natural amino acids, non-natural amino acids, synthetic amino acids, and combinations thereof. The term “peptide” is generally used to refer to a polypeptide having a length of less than about 100 amino acids, less than about 50 amino acids, less than 20 amino acids, or less than 10 amino acids. In some embodiments, proteins are antibodies, antibody fragments, biologically active portions thereof, and/or characteristic portions thereof.
  • Protein: The term “protein” as used herein refers to one or more polypeptides that function as a discrete unit. If a single polypeptide is the discrete functioning unit and does not require permanent or temporary physical association with other polypeptides in order to form the discrete functioning unit, the terms “polypeptide” and “protein” can be used interchangeably. If the discrete functional unit is comprised of more than one polypeptide that physically associate with one another, the term “protein” can be used to refer to the multiple polypeptides that are physically associated and function together as the discrete unit. In some embodiments, proteins can include moieties other than amino acids (e.g., glycoproteins, proteoglycans, etc.) and/or can be otherwise processed or modified. Those of ordinary skill in the art will appreciate that in some embodiments the term “protein” can refer to a complete polypeptide chain as produced by a cell (e.g., with or without a signal sequence), and/or to a form that is active within a cell (e.g., a truncated or complexed form). In some embodiments where a protein is comprised of multiple polypeptide chains, such chains can be covalently associated with one another, for example by one or more disulfide bonds, or can be associated by other means.
  • Reference: as used herein in a scientific context describes a standard or control relative to which a comparison is performed. For example, in some embodiments, an agent, animal, individual, population, sample, sequence or value of interest is compared with a reference or control agent, animal, individual, population, sample, sequence or value. In some embodiments, a reference or control is tested and/or determined substantially simultaneously with the testing or determination of interest. In some embodiments, a reference or control is a historical reference or control, optionally embodied in a tangible medium. Typically, as would be understood by those skilled in the art, a reference or control is determined or characterized under comparable conditions or circumstances to those under assessment. Those skilled in the art will appreciate when sufficient similarities are present to justify reliance on and/or comparison to a particular possible reference or control.
  • Sample: As used herein, the term “sample” typically refers to a biological sample obtained or derived from a source of interest, as described herein. In some embodiments, a source of interest comprises an organism, such as an animal or human. In some embodiments, a biological sample is or comprises biological tissue or fluid. In some embodiments, a biological sample can be or comprise bone marrow; blood; blood cells of any type (e.g., T cells); ascites; tissue or fine needle biopsy samples; cell-containing body fluids; free floating nucleic acids; sputum; saliva; urine; cerebrospinal fluid, peritoneal fluid; pleural fluid; feces; lymph; gynecological fluids; skin swabs; vaginal swabs; oral swabs; nasal swabs; washings or lavages such as a ductal lavages or broncheoalveolar lavages; aspirates; scrapings; bone marrow specimens; tissue biopsy specimens; surgical specimens; feces, other body fluids, secretions, and/or excretions; and/or cells therefrom, etc. In some embodiments, a biological sample is or comprises cells obtained from an individual. In some embodiments, obtained cells are or include cells from an individual from whom the sample is obtained. In some embodiments, a sample is a “primary sample” obtained directly from a source of interest by any appropriate means. For example, in some embodiments, a primary biological sample is obtained by methods selected from the group consisting of biopsy (e.g., fine needle aspiration or tissue biopsy), surgery, collection of body fluid (e.g., blood, lymph, feces etc.), etc. In some embodiments, as will be clear from context, the term “sample” refers to a preparation that is obtained by processing (e.g., by removing one or more components of and/or by adding one or more agents to) a primary sample. For example, filtering using a semi-permeable membrane. Such a “processed sample” can comprise, for example nucleic acids or proteins extracted from a sample or obtained by subjecting a primary sample to techniques such as amplification or reverse transcription of mRNA, isolation and/or purification of certain components, etc.
  • Specific binding: as used herein, refers to a binding agent's ability to discriminate between possible partners, in the environment in which binding is to occur. A binding agent that interacts with one particular target when other potential targets are present is said to “bind specifically” to the target with which it interacts. In some embodiments, specific binding is assessed by detecting or determining degree of association between the binding agent and its partner; in some embodiments, specific binding is assessed by detecting or determining degree of dissociation of a binding agent-partner complex; in some embodiments, specific binding is assessed by detecting or determining ability of the binding agent to compete an alternative interaction between its partner and another entity. In some embodiments, specific binding is assessed by performing such detections or determinations across a range of concentrations.
  • Subject: By “subject” is meant a mammal (e.g., a human, in some embodiments including prenatal human forms). In some embodiments, a subject is suffering from a relevant disease, disorder or condition. In some embodiments, a subject is susceptible to a disease, disorder, or condition. In some embodiments, a subject displays one or more symptoms or characteristics of a disease, disorder or condition. In some embodiments, a subject does not display any symptom or characteristic of a disease, disorder, or condition. In some embodiments, a subject is someone with one or more features characteristic of susceptibility to or risk of a disease, disorder, or condition. In some embodiments, a subject is a patient. In some embodiments, a subject is an individual to whom diagnosis and/or therapy is, will and/or has been administered.
  • Substantially: As used herein, the term “substantially” refers to the qualitative condition of exhibiting total or near-total extent or degree of a characteristic or property of interest. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and/or proceed to completeness or achieve or avoid an absolute result. The term “substantially” is therefore used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
  • Variant: As used herein, the term “variant” refers to an entity that shows significant structural identity with a reference entity but differs structurally from the reference entity in the presence or level of one or more chemical moieties as compared with the reference entity. In many embodiments, a variant also differs functionally from its reference entity. In general, whether a particular entity is properly considered to be a “variant” of a reference entity is based on its degree of structural identity with the reference entity. As will be appreciated by those skilled in the art, any biological or chemical reference entity has certain characteristic structural elements. A variant, by definition, is a distinct chemical entity that shares one or more such characteristic structural elements. To give but a few examples, a small molecule can have a characteristic core structural element (e.g., a macrocycle core) and/or one or more characteristic pendent moieties so that a variant of the small molecule is one that shares the core structural element and the characteristic pendent moieties but differs in other pendent moieties and/or in types of bonds present (e.g., single vs double, E vs Z, etc.) within the core, a polypeptide can have a characteristic sequence element comprised of a plurality of amino acids having designated positions relative to one another in linear or three-dimensional space and/or contributing to a particular biological function, a nucleic acid can have a characteristic sequence element comprised of a plurality of nucleotide residues having designated positions relative to on another in linear or three-dimensional space. For example, a variant polypeptide can differ from a reference polypeptide as a result of one or more differences in amino acid sequence and/or one or more differences in chemical moieties (e.g., carbohydrates, lipids, etc.) covalently attached to the polypeptide backbone. In some embodiments, a variant polypeptide shows an overall sequence identity with a reference polypeptide that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%. Alternatively, or additionally, in some embodiments, a variant polypeptide does not share at least one characteristic sequence element with a reference polypeptide. In some embodiments, the reference polypeptide has one or more biological activities. In some embodiments, a variant polypeptide shares one or more of the biological activities of the reference polypeptide. In some embodiments, a variant polypeptide lacks one or more of the biological activities of the reference polypeptide. In some embodiments, a variant polypeptide shows a reduced level of one or more biological activities as compared with the reference polypeptide. In many embodiments, a polypeptide of interest is considered to be a “variant” of a parent or reference polypeptide if the polypeptide of interest has an amino acid sequence that is identical to that of the parent but for a small number of sequence alterations at particular positions. Typically, fewer than 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% of the residues in the variant are substituted as compared with the parent. In some embodiments, a variant has 10, 9, 8, 7, 6, 5, 4, 3, 2, or 1 substituted residue as compared with a parent. Often, a variant has a very small number (e.g., fewer than 5, 4, 3, 2, or 1) number of substituted functional residues (i.e., residues that participate in a particular biological activity). Furthermore, a variant typically has not more than 5, 4, 3, 2, or 1 additions or deletions, and often has no additions or deletions, as compared with the parent. Moreover, any additions or deletions are typically fewer than about 25, about 20, about 19, about 18, about 17, about 16, about 15, about 14, about 13, about 10, about 9, about 8, about 7, about 6, and commonly are fewer than about 5, about 4, about 3, or about 2 residues. In some embodiments, the parent or reference polypeptide is one found in nature. In some embodiments, the variant is engineered. In some embodiments the variant is naturally occurring. As will be understood by those of ordinary skill in the art, a plurality of variants of a particular polypeptide of interest can be found in nature.
  • Vector: as used herein, refers to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a “plasmid”, which refers to a circular double stranded DNA loop into which additional DNA segments can be ligated. Another type of vector is a viral vector (e.g., a lentiviral vector or a gamma retroviral vector), wherein additional DNA segments can be ligated into the viral genome. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (e.g., bacterial vectors having a bacterial origin of replication and episomal mammalian vectors). Other vectors (e.g., non-episomal mammalian vectors) can be integrated into the genome of a host cell upon introduction into the host cell, and thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as “expression vectors.”
  • Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Enzymatic reactions and purification techniques can be performed according to manufacturer's specifications or as commonly accomplished in the art or as described herein. The foregoing techniques and procedures can be generally performed according to conventional methods well known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification. See e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)), which is incorporated herein by reference for any purpose.
  • Zinc finger protein: As used herein, the term “zinc finger protein” refers to a polypeptide that contains a “zinc finger domain” through which it is capable of binding to nucleic acids (e.g., DNA). The term “zinc finger domain” refers to an individual “finger”, which comprises a ββα-fold stabilized by a zinc ion. Each zinc finger domain typically includes approximately 30 amino acids. Zinc finger domains are largely structurally independent and can retain their structure and function in different environments.
  • As used in this application, the terms “about” and “approximately” are used as equivalents. Any numerals used in this application with or without about/approximately are meant to cover any normal fluctuations appreciated by one of ordinary skill in the relevant art.
  • Other features, objects, and advantages of the present disclosure are apparent in the detailed description that follows. It should be understood, however, that the detailed description, while indicating embodiments of the present disclosure, is given by way of illustration only, not limitation. Various changes and modifications within the scope of the present disclosure will become apparent to those skilled in the art from the detailed description.
    • DETAILED DESCRIPTION OF CERTAIN EMBODIMENTS
  • The present disclosure provides, antibodies that bind TALEN proteins and/or the FokI catalytic DNA cleavage domain and uses thereof
  • As used herein, antibodies include, but are not limited to antibody binding regions that are immunologically functional fragments. The term “immunologically functional fragment” (or “fragment”) of an antibody is a species of antibody comprising a portion (regardless of how that portion is obtained or synthesized) of an antibody that lacks at least some of the amino acids present in a full-length chain but which is still capable of specifically binding to a target antigen (e.g., binding to FokI and/or TALEN proteins). Such fragments are biologically active in that they bind to the target antigen and can compete with other antigen binding molecules, including intact antibodies, for binding to a given epitope. In some embodiments, the fragments are neutralizing fragments. In some embodiments, the fragments can block or reduce the activity of the target antigen (e.g., blocking effect). In some embodiments, the fragments can antagonize the activity the target antigen.
  • In specific embodiments, an anti-TALEN antibody of the instant disclosure is an antibody identified herein as clones 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4. and each comprises the heavy and light chain amino acid, coding, variable, and CDR sequences, as provided and labeled herein. In some embodiments, the clones 2299.2G3.C6, 2299.5D4.C8, 2299.6B3.B8.B6, 2299.6G5.C7, or 2299.7F11.B4 specifically bind a molecule comprising a FokI catalytic domain.
  • Immunologically functional immunoglobulin fragments include, but are not limited to, scFv fragments, Fab fragments (Fab′, F(ab′)2, and the like), one or more complementarity determining regions (“CDRs”), a diabody (heavy chain variable domain on the same polypeptide as a light chain variable domain, connected via a short peptide linker that is too short to permit pairing between the two domains on the same chain), domain antibodies, bivalent antigen binding domains (comprises two antigen binding sites), multispecific antigen binding domains, and single-chain antibodies. These fragments can be derived from any mammalian source, including but not limited to human, mouse, rat, camelid or rabbit. As will be appreciated by one of skill in the art, an antigen binding molecule can include non-protein components.
  • The variable regions typically exhibit the same general structure of relatively conserved framework regions (FR) joined by the 3 hypervariable regions (CDRs). The CDRs from the two chains of each pair typically are aligned by the framework regions, which can enable binding to a specific epitope. From N-terminal to C-terminal, both light and heavy chain variable regions typically comprise the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. By convention, CDR regions in the heavy chain are typically referred to as HC CDR1, CDR2, and CDR3. The CDR regions in the light chain are typically referred to as LC CDR1, CDR2, and CDR3.
  • In some embodiments, anti-TALEN antibodies comprise one or more complementarity binding regions (CDRs) present in the full-length light or heavy chain of an antibody, and in some embodiments comprise a single heavy chain and/or light chain or portion thereof. These fragments can be produced by recombinant DNA techniques or can be produced by enzymatic or chemical cleavage of antigen binding domains, including intact antibodies.
  • In some embodiments, the antigen binding domain is an antibody of fragment thereof, including one or more of the complementarity determining regions (CDRs) thereof. In some embodiments, the antigen binding domain is a single chain variable fragment (scFv), comprising light chain CDRs CDR1, CDR2 and CDR3, and heavy chain CDRs CDR1, CDR2 and CDR3.
  • The assignment of amino acids to each of the framework, CDR, and variable domains is typically in accordance with numbering schemes of Kabat numbering (see, e.g., Kabat et al. in Sequences of Proteins of Immunological Interest, 5th Ed., NIH Publication 91-3242, Bethesda Md. 1991), Chothia numbering (see, e.g., Chothia & Lesk, (1987), J Mol Biol 196: 901-917; Al-Lazikani et al., (1997) J Mol Biol 273: 927-948; Chothia et al., (1992) J Mol Biol 227: 799-817; Tramontano et al., (1990) J Mol Biol 215(1): 175-82; and U.S. Pat. No. 7,709,226), contact numbering, or the AbM scheme (Antibody Modeling program, Oxford Molecular).
  • Accordingly, in some embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the Kabat numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the Chothia numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the contact numbering scheme. In other embodiments, the CDRs of the anti-TALEN antibodies presented herein are numbered according to the AbM numbering scheme.
  • Humanized antibodies of the anti-TALEN antibodies described herein can be prepared by known techniques. In some embodiments, a humanized monoclonal antibody comprises the variable domain of an anti-TALEN antibody (or all or part of the antigen binding site thereof) and a constant domain derived from a human antibody. Alternatively, a humanized antibody fragment can comprise an antigen binding site of a murine or rabbit monoclonal antibody and a variable domain fragment (lacking the antigen binding site) derived from a human antibody. Procedures for the production of engineered monoclonal antibodies include those described in Riechmann et al., (1988) Nature 332:323, Liu et al., (1987) Proc. Nat. Acad. Sci. USA 84:3439, Larrick et al., (1989) Bio/Technology 7:934, and Winter et al., (1993) TIPS 14:139. In some embodiments, the chimeric antibody is a CDR grafted antibody. Techniques for humanizing antibodies are discussed in, e.g., U.S. Pat. Nos. 5,869,619; 5,225,539; 5,821,337; 5,859,205; 6,881,557; Padlan et al., (1995) FASEB J. 9:133-39; Tamura et al., (2000) J. Immunol. 164:1432-41; Zhang et al., (2005) Mol. Immunol. 42(12):1445-1451; Hwang et al., Methods. (2005) 36(1):35-42; Dall'Acqua et al., (2005) Methods 36(1):43-60; and Clark, (2000) Immunology Today 21(8):397-402.
  • Variants of the anti-TALEN antibodies are also within the scope of the disclosure, e.g., variable light and/or variable heavy chains that each have at least 70-80%, 85-90%, 90-95%, 95-97%, 97-99%, or above 99% identity to the amino acid sequences of the antigen binding domain sequences described herein. In some embodiments, the anti-idiotype antibody is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to a heavy chain variable region sequence provided in Table 1a and/or a light chain variable sequence provided in Table 1b.
  • In some instances, such molecules include at least one heavy chain and one light chain, whereas in other instances the variant forms contain two variable light chains and two variable heavy chains (or subparts thereof). A skilled artisan will be able to determine suitable variants of the anti-TALEN antibodies as set forth herein using well-known techniques. In certain embodiments, one skilled in the art can identify suitable areas of the molecule that can be changed without destroying antigen binding activity by targeting regions not believed to be important for activity.
  • An anti-TALEN antibody of the present disclosure can also be a fully human monoclonal antibody. Fully human monoclonal antibodies can be generated by any number of techniques with which those having ordinary skill in the art will be familiar. Such methods include, but are not limited to, Epstein Barr Virus (EBV) transformation of human peripheral blood cells (e.g., containing B lymphocytes), in vitro immunization of human B-cells, fusion of spleen cells from immunized transgenic mice carrying inserted human immunoglobulin genes, isolation from human immunoglobulin V region phage libraries, or other procedures as known in the art and based on the disclosure herein.
  • An anti-TALEN antibody that specifically binds to a TALEN protein and/or the FokI catalytic domain is said to be “selective” when it binds to one target more tightly than it binds to a second target. An anti-TALEN antibody that specifically binds to a TALEN protein and/or the FokI catalytic domain is said to “specifically bind” its target antigen (e.g., TALEN protein and/or the FokI catalytic domain) when the dissociation constant (Kd) is in the nanomolar range (e.g., ˜1 nM). The antigen binding domain specifically binds antigen with “high affinity” when the Kd is 1-5 nM, and with “very high affinity” when the Kd is 0.1-0.5 nM. In one embodiment, the antigen binding domain has a Kd of ˜1 nM. In one embodiment, the off-rate is <1×10−5. In other embodiments, the antigen binding domains will bind to TALEN proteins and molecules comprising FokI catalytic domain with a Kd of between about 1×10−7 M and 1×10−12 M, and in yet another embodiment the antigen binding domains will bind with a Kd between about 1×10−5 and 1×10−12.
  • As provided herein, the anti-TALEN antibodies of the present disclosure specifically bind TALEN proteins and/or the FokI nuclease domain (e.g., SEQ ID NO: 1).
  • In certain embodiments, the anti-TALEN antibodies of the present disclosure bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1×10−6 M, less than 1×10−7 M, less than 1×10−8 M, or less than 1×10−9 M. In one particular embodiment, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1×10−7 M. In another embodiment, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a KD of less than 1×10−8 M. In some embodiments, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with a Kd of about 1×10−7 M, about 2×10−7 M, about 3×10−7 M, about 4×10−7 M, about 5×10−7 M, about 6×10−7 M, about 7×10−7 M, about 8×10−7 M, about 9×10−7 M, about 1×10−8 M, about 2×10−8 M, about 3×10−8 M, about 4×10−8 M, about 5×10−8 M, about 6×10−8 M, about 7×10−8 M, about 8×10−8 M, about 9×10−8 M, about 1×10−9 M, about 2×10−9 M, about 3×10−9 M, about 4×10−9 M, about 5×10−9 M, about 6×10−9 M, about 7×10−9 M, about 8×10−9 M, about 9×10−9 M, about 1×10−10 M, or about 5×10−10 M. In certain embodiments, the Kd is calculated as the quotient of Koff/Kon, and the Kon and Koff are determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., Biacore® surface plasmon resonance technology. In other embodiments, the Kd is calculated as the quotient of Koff/Kon, and the Kon and Koff are determined using a bivalent antibody, such as a Fab fragment, as measured by, e.g., Biacore® surface plasmon resonance technology.
  • In some embodiments, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with an association rate (kon) of less than 1×10−4 M−1 s−1, less than 2×10 −4 M−1 s−, less than 3'10−4 M−1 s−1, less than 4×10−4 M−1 s−1, less than 5×10−4 M−1 s−1, less than 7×10−4 M−1 s−1, less than 8×10−4 M−1 s−1, less than 9×10−4 M−1 s−1, less than 1×10−5 M−1 s−1, less than 2×10−5 M−1 s−1, less than 3×10−5 M−1 s−1, less than 4×10−5 M−1 s−1, less than 5×10−5 M−1 s−1, less than 6×10−5 M−1 s−1, less than 7×10−5 M−1 s−1, less than 8×10−5 M−1 s−1, less than 9×10−5 M−1 s−1, less than 1×10−6 M−1 s−1, less than 2×10−6 M−1 s−1, less than 3×10−6 M−1 s−1, less than 4×10−6 M−1 s−1, less than 5×10−6 M−1 s−1, less than 6×10−6 M−1 s−1, less than 7×10−6 M−1 s−1, less than 8×10−6 M−1 s−1, less than 9×10−6 M−1 s−1, or less than 1×10−7 M−1 s−1. In certain embodiments, the kon can be determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the kon is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • In some embodiments, the anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain with an dissociation rate (koff) of less than 1×10−2 s−1, less than 2×10−2 s−1, less than 3×10−2 s−1, less than 4×10−2 s−1, less than 5×10−2 s−1, less than 6×10−2 s−1, less than 7×10−2 s−1, less than 8×10−2 s−1, less than 9×10−2 s−1, less than 1×10−3 s−1, less than 2×10−3 s−1, less than 3×10−3 s−1, less than 4×10−3 s−1, less than 5×10−3 s−1, less than 6×10−3 s−1, less than 7×10−3 s−1, less than 8×10−3 s−1, less than 9×10−3 s−1, less than 1×10−4 s−1, less than 2×10−4 s−1, less than 3×10−4 s−1, less than 4×10−4 s−1, less than 5×10−4 s−1, less than 6×10−4 s−1 less than 7×10−4 s−1, less than 8×10−4 s−1, less than 9×10−4 s−1, less than 1×10−5 s−1, or less than 5×10−4 s−1. In certain embodiments, the koff is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the koff is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology.
  • Provided herein anti-TALEN antibodies bind TALEN proteins and/or the FokI catalytic domain, comprising a variable heavy chain (VH), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a. The anti-TALEN antibodies that specifically bind to the FokI catalytic domain, comprising a variable heavy chain (VH), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a. In some embodiments, the VH amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH sequence presented in Table la. Kabat CDR definitions are shown in bold and Chothia CDR definitions are underlined.
  • TABLE 1a
    Heavy Chain Variable Regions (VH)
    SEQ ID
    Clone VH Sequence NO:
    Amino Acid Sequence
    2299.2G3.C6 QIQLVQSGPELKKPGETVKISCKASGYTFTDY SIHWVKQ 3
    APGEGLKWMAWI NTETGA PTFADDFKGRLALSLETSANT
    AYLQINNLKHEDTATYFCAK EGGFYFYAMDY WGQGTSVT
    VSS
    2299.5D4.C8 QIQLVQSGPELKKPGETVKISCKASGYTFTDY SIHWVKQ 3
    APGEGLKWMAWI NTETGA PTFADDFKGRLALSLETSANT
    AYLQINNLKHEDTATYFCAK EGGFYFYAMDY WGQGTSVT
    VSS
    2299.6B3.B8.B6 QIQLVQSGPELKKPGETVKISCKASGYAFTDY SIHWMKQ 4
    APGEGLQWMGWI NTETAK PAFGDDFKGRFAFSLETSANT
    AHLHINNLRTEDTATYFCAK EGGFYFYAMDY WGQGTSVT
    VSS
    2299.6G5.C7 QIQLVQSGPELKKPGETVKISCKASGYTFTDY SIHWVKQ 5
    APGKGLKWMGWI NTETGA PTFADDFKGRFAFSLETSAST
    AFLQINNLKNEDTATYFCAK EGGFYFYAMDY WGQGTSLT
    VSS
    2299.7F11.B4 QIQLVQSGPELKKPGETVKISCKASGYTFTDY SIHWVKQ 6
    APGKGLKWMAWI NTETGD PTYEDDFKGRFAFSLETSAST
    AYLQINNLKNEDTATYFCSK EGGFYFYAMDY WGQGTSVT
    VSS
    Polynucleotide Sequence
    2299.2G3.C6 CAGATCCAGTTGGTGCAGTCTGGACCTGAGTTGAAGAAG 29
    CCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGT
    TATACCTTCACAGACTATTCAATACACTGGGTGAAGCAG
    GCTCCAGGAGAGGGTTTAAAGTGGATGGCCTGGATAAAC
    ACTGAGACTGGTGCGCCAACATTTGCAGATGACTTCAAG
    GGACGGTTAGCCCTCTCTTTGGAGACTTCTGCCAACACT
    GCCTATTTGCAGATCAACAACCTCAAACATGAAGACACG
    GCTACATATTTCTGTGCTAAAGAAGGTGGTTTCTACTTT
    TATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACC
    GTCTCCTCA
    2299.5D4.C8 CAGATCCAGTTGGTGCAGTCTGGACCTGAGTTGAAGAAG 31
    CCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGT
    TATACCTTCACAGACTATTCAATACACTGGGTGAAGCAG
    GCTCCAGGAGAGGGTTTAAAGTGGATGGCCTGGATAAAC
    ACTGAGACTGGTGCGCCAACATTTGCAGATGACTTCAAG
    GGACGGTTAGCCCTCTCTTTGGAGACCTCTGCCAACACT
    GCCTATTTGCAGATCAACAACCTCAAACATGAAGACACG
    GCAACATATTTCTGTGCTAAAGAAGGTGGTTTCTACTTT
    TATGCTATGGACTATTGGGGTCAAGGAACCTCAGTCACC
    GTCTCTTCA
    2299.6B3.B8.B6 CAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAG 32
    CCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGT
    TATGCCTTCACAGACTATTCAATACACTGGATGAAGCAG
    GCTCCAGGAGAGGGTCTACAGTGGATGGGCTGGATAAAC
    ACTGAGACTGCTAAGCCAGCATTTGGAGATGACTTCAAG
    GGACGGTTTGCCTTTTCTTTGGAAACCTCTGCCAACACT
    GCCCATTTGCACATCAACAACCTCAGAACTGAAGACACG
    GCTACATATTTCTGTGCTAAAGAAGGTGGTTTCTACTTT
    TATGCTATGGACTATTGGGGTCAAGGAACCTCAGTCACC
    GTCTCCTCA
    2299.6G5.C7 CAGATCCAGTTGGTGCAGTCTGGACCTGAGTTGAAGAAG 33
    CCTGGAGAGACAGTCAAGATCTCCTGCAAGGCTTCTGGT
    TATACCTTCACAGACTATTCAATACACTGGGTGAAGCAG
    GCTCCAGGAAAGGGTTTAAAGTGGATGGGCTGGATAAAC
    ACTGAGACTGGTGCGCCAACATTTGCAGATGACTTCAAG
    GGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACT
    GCCTTTTTGCAGATCAACAACCTCAAAAATGAAGACACG
    GCTACATATTTCTGTGCTAAGGAAGGTGGTTTCTACTTT
    TACGCTATGGACTACTGGGGTCAAGGAACCTCGCTCACC
    GTCTCCTCA
    2299.7F11.B4 CAGATCCAGTTGGTGCAGTCTGGACCTGAGCTGAAGAAG 34
    CCTGGAGAGACAGTCAAGATCTCCTGCAAGGCCTCTGGT
    TATACCTTCACAGACTACTCAATACACTGGGTGAAGCAG
    GCTCCAGGAAAGGGTTTAAAGTGGATGGCCTGGATAAAC
    ACTGAGACTGGTGACCCAACATATGAAGATGACTTCAAG
    GGACGGTTTGCCTTCTCTTTGGAAACCTCTGCCAGCACT
    GCCTATTTGCAGATCAACAACCTCAAAAATGAGGACACG
    GCTACATATTTCTGTTCTAAAGAAGGTGGTTTCTACTTT
    TATGCTATGGACTACTGGGGTCAAGGAACCTCAGTCACC
    GTCTCCTCA
  • Provided herein are anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain, comprising a variable light chain (VL), wherein the amino acid sequence or polynucleotide sequence of the VL is selected from the VL sequences presented in Table 1b. In some embodiments, the VL amino acid sequence is at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL sequence presented in Table lb. Kabat CDR definitions are shown in bold and Chothia CDR definitions are underlined.
  • TABLE 1b
    Light Chain Variable Regions (VL)
    SEQ ID
    Clone VL Sequence NO:
    Amino Acid Sequence
    2299.2G3.C6 DIVMSQSPSSRAVSAGEKVTMSC KSSQSLLSSRTRKNYLA WYQ 7
    QKPGQAPKMLIS WASTREF GVPDRFTGSGFGTDFTLTISSVQG
    EDLAVYYC KQSYNFRT FGGGTKLEIK
    2299.5D4.C8 DIVMSQSPSSLAVSAGEKVTMSC KSSQSLLSSRTRKNYLA WYQ 8
    QKPGQAPKLLIS WASTRES GVPDRFTGSGSGTEFTLTISSVQA
    EDLAVYYC KQSYNLRT FGGGTKLEIK
    2299.6B3.B8.B6 DIVMSQSPSSLAVSAGEKVTMNC KSSQSLLSSRTRKNYLA WYQ 9
    QKPGQSPKLLIY WASTRDS GVPDRFTGSGSGTDFTLTISSVQA
    EDLAVYYC KQSYNFRT FGGGTKLEIK
    2299.6G5.C7 DIVMSQSPSSLAVSTGEKVTMSC KSSQSLLSSRTRKNYLA WYQ 10
    QKPGQAPKLLIS WASTRES GVPDRFTGSGSGTDFTLTISSVQA
    EDLAVYYC KQSFNLRT FGGGTKLEIK
    2299.7F11.B4 DIVMSQSPSSLAVSAGEKVTMSC KSSQSLLSSRTRKNYLA WYQ 11
    QKPGQSPKLLIK WASTRES GVPDRFTGSGSGTDFTLTISSVQA
    EDLAVYYC KQSYNLRT FGGGTKLEIK
    Polynucleotide Sequence
    2299.2G3.C6 GACATTGTGATGTCACAGTCTCCATCCTCCCGGGCTGTGTCAG 30
    CAGGAGAGAAGGTCACTATGAGCTGCAAATCCAGTCAGAGTCT
    GCTCAGCAGTCGAACCCGAAAGAACTACTTGGCTTGGTACCAA
    CAGAAACCAGGGCAGGCTCCTAAAATGCTGATTTCCTGGGCAT
    CCACTAGGGAATTTGGGGTCCCTGATCGCTTCACAGGCAGTGG
    ATTTGGGACAGATTTCACTCTCACCATTAGCAGTGTGCAGGGT
    GAGGACCTGGCAGTTTATTACTGCAAACAATCTTATAATTTTC
    GGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA
    2299.5D4.C8 GACATTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTGTCAG 35
    CAGGAGAGAAGGTCACTATGAGCTGCAAGTCCAGTCAGAGTCT
    GCTCAGCAGTCGAACCCGAAAGAACTACTTGGCTTGGTACCAA
    CAGAAACCAGGGCAGGCTCCTAAACTGCTGATCTCCTGGGCAT
    CCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGG
    ATCTGGGACAGAATTCACTCTCACCATCAGCAGTGTGCAGGCT
    GAGGACCTGGCAGTTTATTACTGCAAACAATCTTATAATCTTC
    GGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA
    2299.6B3.B8.B6 GACATTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTGTCAG 36
    CAGGAGAGAAGGTCACTATGAACTGCAAATCCAGTCAGAGTCT
    GCTCAGCAGTAGAACCCGAAAGAACTACTTGGCTTGGTACCAG
    CAGAAACCAGGGCAGTCTCCTAAACTGCTGATCTACTGGGCTT
    CCACTAGGGACTCTGGGGTCCCTGATCGCTTCACAGGCAGTGG
    ATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCA
    GAGGACCTGGCAGTTTATTACTGCAAGCAATCTTATAATTTTC
    GGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA
    2299.6G5.C7 GACATTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTATCAA 37
    CAGGAGAGAAGGTCACTATGAGCTGCAAATCCAGTCAGAGTCT
    GCTCAGCAGTCGAACCCGAAAGAACTACTTGGCTTGGTACCAA
    CAGAAACCAGGGCAGGCTCCTAAACTGCTGATCTCCTGGGCAT
    CCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGG
    ATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCT
    GAAGACCTGGCAGTTTATTACTGCAAACAATCTTTTAATCTTC
    GGACGTTCGGTGGAGGCACCAAACTGGAAATCAAA
    2299.7F11.B4 GACATTGTGATGTCACAGTCTCCATCCTCCCTGGCTGTGTCAG 38
    CAGGAGAGAAGGTCACTATGAGCTGCAAATCCAGTCAGAGTCT
    GCTCAGCAGTAGAACCCGAAAGAACTACTTGGCTTGGTACCAG
    CAGAAACCAGGGCAGTCTCCTAAACTGCTGATTAAATGGGCAT
    CCACTAGGGAATCTGGGGTCCCTGATCGCTTCACAGGCAGTGG
    ATCTGGGACAGATTTCACTCTCACCATCAGCAGTGTGCAGGCT
    GAAGACCTGGCAGTTTATTACTGCAAGCAATCTTATAATCTTC
    GGACGTTCGGTGGAGGCACCAAGCTGGAAATCAAA
  • Provided herein are anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain, wherein anti-TALEN antibodies comprise a variable heavy chain (VH) and a variable light chain (VL), wherein the amino acid sequence or polynucleotide sequence of the VH is selected from the VH sequences presented in Table 1a; and wherein the amino acid sequence or polynucleotide sequence of the VL is selected from the VL sequences presented in Table 1b.
  • In some embodiments, the anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain, comprise a VH CDR 1, CDR2, and CDR3 of a VH sequence presented in Table 1a. In some embodiments, the VH CDR 1, CDR2, and CDR3 are selected from a CDR sequence presented in Table 1c.
      • (ii)
  • TABLE 1c
    Heavy Chain CDRs
    CDR1 VH SEQ CDR1 VH SEQ
    Sequence ID Sequence ID
    Clone (Chothia) NO: (Kabat) NO:
    2299.2G3.C6 GYTFTDY 12 DYSIH 14
    2299.5D4.C8 GYTFTDY 12 DYSIH 14
    2299.6B3.B8.B6 GYAFTDY 13 DYSIH 14
    2299.6G5.C7 GYTFTDY 12 DYSIH 14
    2299.7F11.B4 GYTFTDY 12 DYSIH 14
    CDR2 VH SEQ CDR2 VH SEQ
    Sequence ID Sequence ID
    Clone (Chothia) NO: (Kabat) NO:
    2299.2G3.C6 NTETGA 15 WINTETGAPTF 18
    ADDFKG
    2299.5D4.C8 NTETGA 15 WINTETGAPTF 18
    ADDFKG
    2299.6B3.B8.B6 NTETAK 16 WINTETAKPAF 19
    GDDFKG
    2299.6G5.C7 NTETGA 15 WINTETGAPTF 18
    ADDFKG
    2299.7F11.B4 NTETGD 17 WINTETGDPTY 20
    EDDFKG
    CDR3 VH SEQ CDR3 VH SEQ
    Sequence ID Sequence ID
    Clone (Chothia) NO: (Kabat) NO:
    2299.2G3.C6 EGGFYFYAMDY 21 EGGFYFYAMDY 21
    2299.5D4.C8 EGGFYFYAMDY 21 EGGFYFYAMDY 21
    2299.6B3.B8.B6 EGGFYFYAMDY 21 EGGFYFYAMDY 21
    2299.6G5.C7 EGGFYFYAMDY 21 EGGFYFYAMDY 21
    2299.7F11.B4 EGGFYFYAMDY 21 EGGFYFYAMDY 21
  • In some embodiments, anti-TALEN antibodies that specifically bind to the Fok1 catalytic domain, comprise a VL CDR 1, CDR2, and CDR3 of a VL sequence presented in Table 1b. In some embodiments, the VH CDR 1, CDR2, and CDR3 are selected from a CDR sequence presented in Table 1d.
  • TABLE 1d
    Light Chain CRs
    SEQ ID
    Clone NO:
    CDR1 VL Sequence
    (Kabat and Chothia)
    2299.2G3.C6 KSSQSLLSSRTRKNYLA 22
    2299.5D4.C8 KSSQSLLSSRTRKNYLA 22
    2299.6B3.B8.B6 KSSQSLLSSRTRKNYLA 22
    2299.6G5.C7 KSSQSLLSSRTRKNYLA 22
    2299.7F11.B4 KSSQSLLSSRTRKNYLA 22
    CDR2 VL Sequence
    (Kabat and Chothia)
    2299.2G3.C6 WASTREF 23
    2299.5D4.C8 WASTRES 24
    2299.6B3.B8.B6 WASTRDS 25
    2299.6G5.C7 WASTRES 24
    2299.7F11.B4 WASTRES 24
    CDR3 VL Sequence
    (Kabat and Chothia)
    2299.2G3.C6 KQSYNFRT 26
    2299.5D4.C8 KQSYNLRT 27
    2299.6B3.B8.B6 KQSYNFRT 26
    2299.6G5.C7 KQSFNLRT 28
    2299.7F11.B4 KQSYNLRT 27
  • Practice of the methods, as well as preparation and use of the compositions disclosed herein employ, unless otherwise indicated, conventional techniques in molecular biology, biochemistry, computational chemistry, protein engineering, antibody structure and function, cell culture, recombinant DNA and related fields as are within the skill of the art. These techniques are fully explained in the literature. See, for example, Sambrook et al. MOLECULAR CLONING: A LABORATORY MANUAL, Second edition, Cold Spring Harbor Laboratory Press, 1989 and Third edition, 2001 and subsequent editions; Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, John Wiley & Sons, New York, 1987 and periodic updates; the series METHODS IN ENZYMOLOGY, Academic Press, San Diego; Wolffe, CHROMATIN STRUCTURE AND FUNCTION, Third edition, Academic Press, San Diego, 1998 and subsequent editions.
    • Genome Editing Technologies Transcription Activator-Like Effector Nucleases
  • Transcription activator-like effector nucleases (TALEN) typically refer to restriction enzymes that can be engineered to cut specific sequences of DNA. They generally include a TAL effector DNA-binding domain and a DNA cleavage domain, i.e., a nuclease which cuts DNA strands. Transcription activator-like effectors (TALEs) can be engineered to bind practically any desired DNA sequence. Thus, TALENs can be introduced into cells, for use in gene editing or for genome editing in situ.
  • Various non-specific DNA cleavage domain can be used in TALEN constructs including, but not limited to, wild-type FokI cleavage domain, portions of the FokI endonuclease, FokI cleavage domain variants such as those with mutations designed to improve cleavage specificity and cleavage activity. In some embodiments, a FokI domain functions as a dimer, involving two constructs with DNA binding domains for sites in a target genome with proper orientation and spacing. In some embodiments, the TALEN comprises an endonuclease (e.g., FokI) cleavage domain or cleavage half-domain. The disclosed antibodies can be used for any TALEN-mediated gene editing, including targeted integration; methods and compositions for nuclease-mediated targeted integration are described in WO2015127439A1, which is incorporated by reference in its entirety.
    • Zinc Finger Nucleases
  • Zinc finger nucleases (ZFNs) are protein chimera comprised of a zinc finger-based DNA-binding domain and a DNA-cleavage (i.e. nuclease) domain (e.g., FokI). ZFNs are able to introduce double-strand breaks (DSB; breaks at the same or very close points in both strands of a double-stranded DNA molecule) at specific locations within a DNA molecule which can subsequently be used to disable, replace, insert or edit a targeted genomic region.
  • Zinc fingers are among the most common DNA binding motifs found in eukaryotes. These proteins are classified according to the number and position of the cysteine and histidine residues available for zinc coordination. A zinc finger consists of two antiparallel β strands, and an a helix. The zinc ion is crucial for the stability of this domain type—in the absence of the metal ion the domain unfolds as it is too small to have a hydrophobic core. One very well-explored subset of zinc-fingers (the C2H2 class) comprises a pair of cysteine residues in the beta strands and two histidine residues in the alpha helix which are responsible for binding a zinc ion. The two other classes of zinc finger proteins are the C4 and C6 classes. Zinc fingers are important in regulation because when interacted with DNA and zinc ion, they provide a unique structural motif for DNA-binding proteins. The structure of each individual finger is highly conserved and consists of about 30 amino acid residues, constructed as a ββα fold and held together by the zinc ion. The α-helix occurs at the C-terminal part of the finger, while the β-sheet occurs at the N-terminal part.
  • The DNA-binding domain of a ZFN can be composed of two to eight zinc finger motifs due to their supposed modularity. In some embodiments, a ZFN comprises 2, 3, 4, 5, 6, 7, or 8 zinc finger motifs. Each zinc finger motif is typically considered to recognize and bind to a three-base pair sequence and as such, a protein including more zinc fingers targets a longer sequence and therefore has a greater specificity and affinity to the target site. Methods to engineer zinc finger binding domains to bind to a sequence of choice are well known in the art. See, for example, Beerli et al. (2002) Nature Biotechnol. 20:135-141; Pabo et al. (2001) Ann. Rev. Biochem. 70:313-340; Isalan et al. (2001) Nature Biotechnol. 19:656-660; Segal et al. (2001) Curr. Opin. Biotechnol. 12:632-637; Choo et al. (2000) Curr. Opin. Struct. Biol. 10:411-416. Zinc finger engineering methods known in the art include, but are not limited to, rational design and various types of selection. Rational design includes, for example, using databases comprising triplet (or quadruplet) nucleotide sequences and individual zinc finger amino acid sequences, in which each triplet or quadruplet nucleotide sequence is associated with one or more amino acid sequences of zinc fingers which bind the particular triplet or quadruplet sequence. See, for example, U.S. Pat. Nos. 6,453,242 and 6,534,261. Depending upon the required specifications of the end-product, the included zinc fingers can be selected via a parallel, sequential or bipartite technique or through an in vitro cell-based technique. Exemplary selection methods are also known in the art, including phage display and two-hybrid systems, see, U.S. Pat. Nos. 5,925,523; 6,007,988; 6,013,453; 6,410,248; 6,140,466; 6,200,759; and 6,242,568; and international patent publications WO 98/37186; WO 98/53057; WO 00/27878; and WO 01/88197. Enhancements of binding specificity for zinc finger binding domains have been previously described, for example, in WO 02/077227.
  • The non-specific nuclease domain of FokI is functionally independent of its natural DNA-binding domain and therefore can be employed in the construction of ZFNs. Since the domain must dimerize to accomplish a double-strand break it is necessary that a nuclease is also bound to the opposite strand by virtue of another ZFN molecule bound to its target sequence as shown in the diagram. The two target sites need not be the same, so long as ZFNs targeting both sites are present. In order to form a dimer, two ZFN molecules must meet with their respective recognition sites not less than 4-6 base pairs apart but also not so far apart that they may not dimerize. While one ZFN molecule binds its target sequence on one strand, another ZFN molecule binds its target sequence on the opposite strand, as shown in the diagram. The nuclease domains dimerize and each cleaves its own strand, producing a DSB. FokI can be employed as a homo- or a heterodimer. In some embodiments, FokI is a homodimer. In some embodiments, FokI is a heterodimer.
    • RNA-Guided FokI Nuclease
  • RNA-guided FokI nucleases (RFNs) are protein chimera comprised of a Cas9 nuclease (Cas9) DNA-binding domain and a DNA-cleavage domain (e.g., FokI-cleavage domain). RFNs specifically target particular DNA sequences through the use of a guide RNA (gRNA) bearing 17-20 nucleotides of target site complementarity at the 5′ end. RFNs require dimerization of the FokI DNA cleavage domain to introduce double-strand breaks (DSB; breaks at the same or very close points in both strands of a double-stranded DNA molecule) at specific locations within a DNA molecule which can subsequently be used to disable, replace, insert or edit a targeted genomic region.
    • CRISPR
  • CRISPR-associated Cas systems have evolved in bacteria and archaea to use short RNAs to guide DNA cleavage complexes to specific nucleotide sequences. The CRISPR/Cas system has been adapted for genome editing in eukaryotic cells. Cas9 unwinds DNA and checks for complementarity to the 20 base pair spacer region of the gRNA thus specifically targeting DNA sequences preceding protospacer adjacent motifs (PAM) sequences in mammalian cell genomes. The introduction of DSBs allows for target sequence alteration through one of two endogenous DNA repair mechanisms—either non-homologous end-joining (NHEJ) or homology-directed repair (HDR). The CRISPR/Cas system has also been used for gene regulation including transcription repression and activation without altering the target sequence. Targeted gene regulation based on the CRISPR/Cas system uses an enzymatically inactive Cas9 (dCas9). Additional Cas9 descriptions and gRNA requirements for programmable dCas9 are incorporated in but not limited to U.S. patent Ser. No. 14/536319, Ser. No. 14/320498, and Ser. No. 14/320467
    • Genome Editing Systems
  • As described above, TALENs, ZFNs and RFNs can bind to and cleave at targeted sites in a genome, permitting the insertion or deletion of specific DNA sequences, notably when a repair template is provided. Selective cutting is achieved through sequence specific targeting by the DNA binding domain (e.g., TAL effector DNA-binding domain) and DNA cleavage by FokI nucleases. After the TALEN construct creates a double stranded break at the target locus, the homologous recombination machinery searches for homology between the damaged chromosome and the extra-chromosomal fragment and copies the sequence of the fragment between the two broken ends of the chromosome, regardless of whether the fragment contains the original sequence, resulting in insertion of the gene of interest into the genome.
  • In addition to homology-mediated gene editing the TALEN approach can also be applied to gene editing (knock outs and insertions) mediated by non-homologous end joining.
  • In some embodiments, the genome editing system includes 1, 2, 3, 4, 5, 6, 7, 8 or more nucleic acid construct(s) encoding a “half-TALEN” which assemble to form a complete TALEN with targeted FokI-mediated nuclease activity. In some embodiments, the genome editing system includes two or four nucleic acid constructs encoding “half-TALENs” with targeted FokI-mediated nuclease activity. In some embodiments, the nucleic acids encode dimeric TALENs, or a TALEN comprising two “half-TALENs”.
  • In some embodiments, a genome editing system includes a polynucleotide construct bearing a donor sequence which undergoes genomic insertion after nuclease cleavage. In some embodiments, a donor sequence will have one or more homologous region(s) that share identity to a genomic sequence with which recombination is desired. In some embodiments, a donor sequence will have one or more homologous region(s) that have at least 50% sequence identity to a genomic sequence with which recombination is desired. In some embodiments, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 99.9% sequence identity is present over a homologous region. Any value between 1% and 100% sequence identity can be present, depending upon the length of the donor polynucleotide.
  • In some embodiments, as part of gene therapy, DNA can be introduced into selected target cells in a manner such that the donor DNA is expressed, and a therapeutic product encoded thereby is produced. Additionally, or alternatively, donor DNA can in some manner mediate expression of DNA that encodes the therapeutic product, or it can encode a product, such as a peptide or RNA that in some manner mediates, directly or indirectly, expression of a therapeutic product. In some embodiments the donor DNA encodes a therapeutic product for the treatment or prevention of disease or disorder that results from a genetically defect or deficiency. In some embodiments, the donor DNA encodes a therapeutic product for the treatment or prevention of cancer or any other disease or disorder that results from a genetic defect or deficiency. In some embodiments, the donor DNA encodes a chimeric antigen receptor (CAR).
  • Techniques and protocols for genome editing are described in the art. See, for example, US 2005/0215502; US 2007/0134796; WO 2005/084190; WO2014204578, Urnov et al., Nature Reviews Genetics 11, 636-646 (2010); Rahman et al., Human Gene Therapy 22(8): 925-933 (2011); Tsai et al., Nature Biotechnology (2014) 32: 569-576; and Collins et al., Proceedings Biological Sciences/The Royal Society, 282(1821):pii 20143003 (2015). For example, genome editing can be performed in vivo or ex vivo (e.g. in vitro). In some embodiments, viral and non-viral based gene transfer methods can be used to introduce nucleic acids encoding TALENs, ZFNs or RFNs into mammalian cells or target tissues. Such methods can be used to administer nucleic acids encoding TALENs, ZFNs or RFNs to cells in vitro. In some embodiments, non-viral vector delivery systems include DNA plasmids, naked nucleic acid, and nucleic acid complexed with a delivery vehicle such as poloxamers or liposomes. In some embodiments, the nucleic acids encoding TALENs, ZFNs or RFNs are transfected via electroporation. In some embodiments, the non-viral delivery system includes direct transfer of TALEN-, ZFN- or RFN-encoding mRNA, such as by microinjection. Viral vector delivery systems include DNA and RNA viruses, which have either episomal or integrated genomes after delivery to the cell. Examples of viral vector delivery systems include, but are not limited to, integrase-deficient lentiviral vectors, adenoviral vectors, and vectors based on adeno-associated virus. In some embodiments, components of the genome editing system are mixed prior to administering to a subject. In some embodiments, components of the genome editing system are administered separately. Separate administration of the genome editing components can be essentially simultaneous, sequential or separated by a determined period of time.
  • Described herein, are highly sensitive and reliable methods for detecting and/or measuring FokI in a sample. As shown herein, these methods can detect FokI at physiological levels.
    • Detection Moieties
  • Detection moieties as used herein include moieties of any structure capable of being detected by any methods known in the art. A detection moiety refers to any element, molecule, functional group, compound, fragment or moiety that is detectable.
  • Detection moieties include, but are not limited to, radionuclides (e.g., 3H, 14C, 18F, 19F, 32P, 35S, 135I, 125I, 123I, 64Cu, 187Re, 111In, 90Y, 99mTc, 177Lu, 89Zr etc.), fluorescent dyes (such as, for example fluorescein dyes, acridine dyes, SYBR dyes, rhodamine dyes, oxazine dyes, etc.), chemiluminescent agents (such as, for example, acridinum esters, stabilized dioxetanes, and the like), electrochemiluminescent agents (such as, for example, Sulfo Tags), bioluminescent agents (such as, for example, luciferin), spectrally resolvable inorganic fluorescent semiconductors nanocrystals (i.e., quantum dots), metal nanoparticles (e.g., gold, silver, copper, platinum, etc.), nanoclusters, paramagnetic metal ions, enzymes (such as, for example, horseradish peroxidase, alkaline phosphatase, etc.), colorimetric labels (such as, for example, dyes, colloidal gold, and the like), biotin, dioxigenin, haptens, and proteins for which antisera or monoclonal antibodies are available.
  • In some embodiments, the anti-FokI antibody is associated with a detection moiety. The anti-FokI antibody can be covalently or non-covalently associated with the detection moiety. In some embodiments the detection moiety is selected from sulfo-tag, horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin.
  • In some embodiments, the detection moiety is an electrochemiluminescent (ECL) label. In general, ECL-based assays involve the use of electrochemiluminescent compounds as labels (referred to herein as ECL labels). Any compounds capable of electrochemiluminescence can be used as an ECL labels. Examples of ECL labels include, but are not limited to, organometallic compounds such as the tris-bipyridyl-ruthenium (RuBpy) moiety where the metal is from, for example, the metals of group VII and VIII, including Re, Ru, Ir and Os. In some embodiments, the ECL label is a Sulfo-Tag label. Species that react with the ECL label in the ECL process are referred to herein as ECL coreactants. Commonly used coreactants for ECL include tertiary amines (e.g. tripropylamine (TPA)), oxalate, and persulfate.
  • In some embodiments, the anti-TALEN antibody is associated with a detection moiety. The detection moiety can be associated with the anti-TALEN antibody through covalent conjugation or through non-covalent association. Covalent conjugation of the detection moiety to the anti-TALEN antibody can be direct or can be through a linker. In some embodiments the detection moiety is selected from an ECL tag (e.g., Sulfo-Tag), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin.
  • The anti-TALEN antibodies described herein can be used in any assay known in the art to measure presence or intensity of a detection moiety in immunoassays. In some embodiments, detecting the presence or absence of a FokI comprising molecule (e.g., a TALEN protein) comprises measurement of electrochemiluminescence, luminescence, fluorescence, or absorbance by any means known in the art. The detecting step can involve a quantitative measurement, which can be used to determine the amount of FokI polypeptide in the sample. Measurement(s) to determine the presence or intensity of FokI can be performed by a hand method or can be carried out using an apparatus such as an analyzer. For example, in some embodiments, the detection moiety can produce a color output. Methods can include visual appearance of a colored product and/or an instrument such as an analyzer can be used to detect or quantify the color product. In some embodiments, the detecting step comprises a measurement of electrochemiluminescence, which can be performed using a commercially available instrument.
  • In some embodiments, the detection moiety is a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, or a hapten. In some embodiments, the detectable label is a fluorescent label is selected from the group consisting of an Atto dye, an Alexa Fluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP,Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2, mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.
    • Type-2 Restriction Enzyme FokI
  • FokI is a bacterial type IIS restriction endonuclease that is naturally found in Flavobacterium okeanokoites. Natural FokI consists of an N-terminal DNA-binding domain and a non-specific DNA cleavage domain at the C-terminus. (UniProt Accession Number P14870) The full length wild type FokI amino acid sequence is:
  • (SEQ ID NO: 2)
    MFLSMVSKIRTFGWVQNPGKFENLKRVVQVFDRNSKVHNEVKNIKIPTLV
    KESKIQKELVAIMNQHDLIYTYKELVGTGTSIRSEAPCDAIIQATIADQG
    NKKGYIDNWSSDGFLRWAHALGFIEYINKSDSFVITDVGLAYSKSADGSA
    IEKEILIEAISSYPPAIRILTLLEDGQHLTKFDLGKNLGFSGESGFTSLP
    EGILLDTLANAMPKDKGEIRNNWEGSSDKYARMIGGWLDKLGLVKQGKKE
    FIIPTLGKPDNKEFISHAFKITGEGLKVLRRAKGSTKFTRVPKRVYWEML
    ATNLTDKEYVRTRRALILEILIKAGSLKIEQIQDNLKKLGFDEVIETIEN
    DIKGLINTGIFIEIKGRFYQLKDHILQFVIPNRGVTKQLVKSELEEKKSE
    LRHKLKYVPHEYIELIEIARNSTQDRILEMKVMEFFMKVYGYRGKHLGGS
    RKPDGAIYTVGSPIDYGVIVDTKAYSGGYNLPIGQADEMQRYVEENQTRN
    KHINPNEWWKVYPSSVTEFKFLFVSGHFKGNYKAQLTRLNHITNCNGAVL
    SVEELLIGGEMIKAGTLTLEEVRRKENNGEINF
  • The FokI DNA cleavage domain can function independently of the DNA binding domain. In some embodiments, a FokI polypeptide consists, consists essentially of or comprises the FokI nuclease domain. In some embodiments, the FokI catalytic domain polypeptide is wild-type amino acids 439-583 of SEQ ID NO: 2. In some embodiments, the anti-TALEN antibodies described herein bind to a molecule comprising SEQ ID NO:1.
  • (SEQ ID NO: 1)
    MKVMEFFMKVYGYRGKHLGGSRKPDGAIYTVGSPIDYGVIVDTKAYSGGY
    NLPIGQADEMQRYVEENQTRNKHINPNEWWKVYPSSVTEFKFLFVSGHFK
    GNYKAQLTRLNHITNCNGAVLSVEELLIGGEMIKAGTLTLEEVRRKENNG
    EINF
  • In some embodiments, the FokI protein is modified. In some embodiments, the modified FokI protein includes an amino acid sequence at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% identical to wild-type FokI catalytic domain (SEQ ID NO:1). In some embodiments, the FokI protein comprises biologically active fragments of FokI. In some embodiments the biologically active fragment includes the catalytic domain of FokI. In some embodiments, FokI protein includes the DNA-cleavage domain of FokI. In some embodiments, the FokI protein comprises an amino acid sequences that differs from SEQ ID NO: 1 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, or more amino acids.
    • Sample Types
  • Sample types of the present disclosure include any materials that have, are suspected to have, are likely to have, or are confirmed to have TALEN proteins or molecules comprising a FokI catalytic domain. In some embodiments, the sample is an in vitro sample. In some embodiments, the sample is an in vivo sample. In some embodiments, the sample is of biological origin (e.g., a biological sample). Biological samples include all materials that at one time were part of a living organism. In some embodiments, the biological sample is from a mammal. Mammals include, but are not limited to, humans, dogs, cats, cows, pigs, sheep, non-human primates and llamas. Humans can be of any age. The biological sample can take any form and include, but are not limited to, cells, tissue, whole blood, plasma, serum, urine, stool, saliva, cord blood, sperm, aqueous or vitreous humor, chorionic villus sample, and combination thereof. In some embodiments, the sample is a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media. In some embodiments, a sample e.g., a serum sample is to be analyzed for the presence (or absence) or level of TALEN or FokI protein.
    • Kits
  • Also provided herein are kits for use in detecting and/or measuring FokI in a sample (e.g., a biological sample), as described herein. Such kits typically comprise one or more substances, reagents and/or materials for use in the methods provided herein. The kit can include instructions for performing such methods. Kits for detecting and/or measuring FokI can include various reagents necessary for the analyzing 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000 or more samples. In some embodiments, the kit can allow for the simultaneous or near simultaneous analysis of a plurality of samples, such as a microplate-type assay kit. In some embodiments, the kit can be disposable, such that reagents and materials are intended for a single use and/or to be disposed of after performance of the assay.
  • In some embodiments, a kit for use in detecting and/or measuring FokI in a sample comprises an anti-TALEN antibody described herein and optionally conjugated to a detection moiety, or can comprise materials allowing a used of the kit to perform such a conjugation. Substrates of the FokI detection kits described herein can take any suitable form that permits the association of anti-FokI antibodies described herein and FokI containing complexes. In some embodiments, the substrate is contained in or part of a microplate. Any suitable detection moiety known in the art can be used. For example, detection moieties include, but are not limited to, an ECL tag (e.g., Sulfo-Tag), horseradish peroxidase, alkaline phosphatase, FITC, digoxigenin, acridan, RPE, luciferin, fluorophores, chromophores, radioisotopes, or biotin. Further, any suitable methods of detection can be used in conjunction with FokI detection kits described herein. The kit may or may not include reagents, materials and or instruments for performing the detection or measurement of signal. In some embodiments, the use of a kit can include the detection of signal, which comprises measurement of electrochemiluminescence, luminescence, fluorescence, or absorbance. Detection of signal associated with an anti-FokI detection assay can be by any means known in the art. Associated kits may or may not include instructions for a specific detection method. In some embodiments, a kit can refer a user to standard methods of detection. In some embodiments, the kit can refer a user to follow instructions associated with other instrumentation for detection.
    • Representative Uses
  • In some embodiments, methods and kits of the present disclosure can be used for the evaluation and/or monitoring of cellular or gene therapy, such as CAR T therapy. In some embodiments the cellular or gene therapy is a ZFN-based gene therapy. In some embodiments, the cellular or gene therapy is a RFN-based gene therapy. In some embodiments, the cellular therapy is a TALEN-based gene therapy. In some embodiments, the cellular or gene therapy comprises the administration of a DNA construct. In some embodiments, the cellular or gene therapy comprises mRNA replacement therapy. In some embodiments, the cellular or gene therapy comprises cellular replacement therapy, such as Chimeric Antigen Receptor (CAR)-based therapy, which can comprise allogeneic or autologous cellular replacement. Cellular replacement therapy can comprise administering cells that have been transduced or transfected with a nucleic acid construct encoding a FokI protein or a biologically active fragment thereof.
  • In some embodiments, samples for evaluating and/or monitoring cellular or gene therapy can be obtained prior to the initiation of therapy. In some embodiments, samples are obtained after a first cellular or gene therapy treatment or dose. In some embodiments, samples are obtained after the conclusion of gene therapy. In some embodiments, samples are obtained at specific time points, intervals, or any other metric of time before, during or after cellular or gene therapy is performed. In some embodiments, FokI detection is used for assessing potential for cellular or gene therapy.
    • Methods of Treatment
  • In some embodiments, the anti-TALEN antibodies of the present disclosure can be used for the evaluation and/or monitoring of gene therapy or cellular replacement therapy, such as CAR therapy. In some embodiments, the gene therapy comprises administering to a patient a population of cells engineered with a TALEN protein to express a chimeric antigen receptor (CAR). The CAR containing immune cells can be used to treat malignancies involving aberrant expression of biomarkers, including cancer. In some embodiments, CAR containing immune cells of the disclosure can be used to treat non-Hodgkins lymphoma such as diffuse large B-cell lymphoma (DLBCL), leukemia (e.g., CLL or ALL), multiple myeloma (MM), small cell lung cancer, melanoma, low grade gliomas, glioblastoma, medullary thyroid cancer, carcinoids, dispersed neuroendocrine tumors in the pancreas, bladder and prostate, testicular cancer, and lung adenocarcinomas with neuroendocrine features.
  • As used herein, the term “cancer” includes, but is not limited to, solid tumors and blood-born tumors. The term “cancer” refers to disease of skin tissues, organs, blood, and vessels, including, but not limited to, cancers of the bladder, bone or blood, brain, breast, cervix, chest, colon, endometrium, esophagus, eye, head, kidney, liver, lymph nodes, lung, mouth, neck, ovaries, pancreas, prostate, rectum, stomach, testis, throat, and uterus. Specific cancers include, but are not limited to, advanced malignancy, amyloidosis, neuroblastoma, meningioma, hemangiopericytoma, multiple brain metastases, glioblastoma multiforms, glioblastoma, brain stem glioma, poor prognosis malignant brain tumor, malignant glioma, recurrent malignant giolma, anaplastic astrocytoma, anaplastic oligodendroglioma, neuroendocrine tumor, rectal adenocarcinoma, Dukes C & D colorectal cancer, unresectable colorectal carcinoma, metastatic hepatocellular carcinoma, Kaposi's sarcoma, karotype acute myeloblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma (NHL), cutaneous T-Cell lymphoma, cutaneous B-Cell lymphoma, diffuse large B-Cell lymphoma, low grade follicular lymphoma, malignant melanoma, malignant mesothelioma, malignant pleural effusion mesothelioma syndrome, peritoneal carcinoma, papillary serous carcinoma, gynecologic sarcoma, soft tissue sarcoma, scleroderma, cutaneous vasculitis, Langerhans cell histiocytosis, leiomyosarcoma, fibrodysplasia ossificans progressive, hormone refractory prostate cancer, resected high-risk soft tissue sarcoma, unrescectable hepatocellular carcinoma, Waldenstrom's macroglobulinemia, smoldering myeloma, indolent myeloma, fallopian tube cancer, androgen independent prostate cancer, androgen dependent stage IV non-metastatic prostate cancer, hormone-insensitive prostate cancer, chemotherapy-insensitive prostate cancer, papillary thyroid carcinoma, follicular thyroid carcinoma, medullary thyroid carcinoma, and leiomyoma. In a specific embodiment, the cancer is metastatic. In another embodiment, the cancer is refractory or resistant to chemotherapy or radiation. In a further embodiment a cancer has been reduced by a degree determined to be less than desire and a re-treatment is determined to be appropriate.
    • EXAMPLES Example 1: Generation of Anti-TALEN Antibodies
  • To generate hybridoma cells, wildtype Balb/c mice were immunized with FokI catalytic domain protein including a C-terminal 6xHis tag and GSGS linker. Using repetitive immunizations multiple sites (REVIMS), cells from immunization day 12 Balb/c mice were fused to obtain hybridoma fusion #2296. The resulting antibodies were screened on FokI catalytic domain for ELISA positives and counter screened using the His-tag antigen. Samples were also screened on full length TALEN protein including a C-terminal 6xHis tag and GSGS linker. Antibodies were analyzed by Western Blot and assessed using Biacore® for binding confirmation and kinetics.
  • Antibodies obtained from fusion #2296 resulted in over 30 ELISA positives screened on FokI and full-length TALEN protein. These antibodies were negative on His-tag antigen. Biacore® analysis of fusion #2296 antibodies resulted in kD values ranging from 5 nM to 100 nM. The Biacore® kinetics of fusion #2296 REVIMS Day 12 are shown in Table 2 below.
  • TABLE 2
    Biacore ® kinetics of Fusion 2296
    Binds FokI
    Ligand Analyte ka (1/Ms) kd (1/s) t1/2 (min) KD (nM) or TALEN (Y/N/A)
    A01_1A8 FokI 5.51E+03 3.51E−04 32.9 63.7 Y
    A01_1A8 TALEN Y
    A02_7E12 FokI 2.72E+03 4.72E−04 24.5 174 Y
    A02_7E12 TALEN Y
    A03_14H5 FokI 5.47E+04 7.09E−04 16.3 13.0 Y
    A03_14H5 TALEN Y
    A05_1G2 FokI 7.87E+05 3.16E−02 0.4 40.2 Y
    A05_1G2 TALEN Y
    B04_22A5 FokI 1.01E+06 4.62E−02 0.3 45.7 Y
    B04_22A5 TALEN Y
    B05_2G3 FokI 1.18E+04 6.15E−04 18.8 52.1 Y
    B05_2G3 TALEN Y
    C03_17B5 FokI 2.02E+05 5.01E−03 2.3 24.8 Y
    C03_17B5 TALEN Y
    C04_22C12 FokI 1.83E+04 4.83E−04 23.9 26.4 Y
    C04_22C12 TALEN Y
    D02_10B4 FokI 5.86E+05 4.36E−03 2.6 7.4 Y
    D02_10B4 TALEN Y
    D04_23D1 FokI 2.63E+04 6.20E−04 18.6 23.6 Y
    D04_23D1 TALEN Y
    E01_2D7 FokI 7.45E+05 1.48E−02 0.8 19.9 Y
    E01_2D7 TALEN Y
    E02_10D7 FokI 5.15E+05 1.96E−02 0.6 38.1 Y
    E02_10D7 TALEN Y
    G01_5E11 FokI 5.35E+05 2.01E−02 0.6 37.6 Y
    G01_5E11 TALEN Y
    G02_11D2 FokI 1.59E+05 8.91E−04 13.0 5.6 Y
    G02_11D2 TALEN Y
    G03_20F9 FokI 1.49E+06 4.65E−02 0.2 31.2 Y
    G03_20F9 TALEN Y
    G04_1A1 FokI 5.00E+03 5.15E−04 22.4 103 Y
    G04_1A1 TALEN Y
    H01_6H4 FokI 2.97E+05 1.87E−03 6.2 6.3 Y
    H01_6H4 TALEN Y
    H02_13B2 FokI 1.06E+06 3.21E−02 0.4 30.3 Y
    H02_13B2 TALEN Y
  • Hybridoma fusion #2299 cells were obtained from a long immunization on day 94. Balb/c mouse #2299 with higher antibody titer was selected for fusion. Antibodies obtained from fusion #2299 resulted in over 68 ELISA positives screened on FokI and full-length TALEN protein. These antibodies were negative on the His tag antigen. Biacore® analysis of fusion #2299 antibodies resulted in kD values ranging from sub nM to 100 nM. Five out of the top 12 ELISA binders were positive in Western Blot analysis with supernatant (FIG. 1 ). The Biacore® kinetics of exemplary antibodies from fusion #2299 are shown in Table 3 below.
  • TABLE 3
    Biacore ® kinetics of Fusion 2299
    Binds FokI
    Ligand Analyte ka (1/Ms) kd (1/s) t1/2 (min) KD (nM) or TALEN (Y/N/A)
    D04_4C7 FokI 3.32E+05 1.26E−04 91.69 0.38 Y
    C09_9H1 FokI 5.72E+04 9.38E−05 123.16 1.64 Y
    A02_1G2 FokI 3.63E+04 6.12E−05 188.77 1.69 Y
    C02_1G12 FokI 5.94E+04 1.16E−04 99.59 1.95 Y
    A04_4B10 FokI 1.02E+05 2.33E−04 49.58 2.28 Y
    G02_2E5 FokI 1.10E+05 2.73E−04 42.32 2.48 Y
    E01_1D1 FokI 7.43E+04 1.91E−04 60.48 2.57 Y
    H08_8H12 FokI 2.39E+06 9.98E−03 1.16 4.18 Y
    B02_1G6 Fok 1.01E+05 4.36E−04 26.50 4.32 Y
    E02_2D12 FokI 7.09E+04 3.29E−04 35.11 4.64 Y
    D01_1C10 FokI 7.47E+04 3.96E−04 29.17 5.30 Y
    G09_2299.8C5 FokI 1.58E+05 1.21E−03 9.55 7.66 Y
    F08_8F3 FokI 2.92E+04 2.59E−04 44.60 8.87 Y
    F09_2299.4D4.1 FokI 1.06E+04 1.39E−04 83.11 13.11 Y
    G07_7D2 FokI 9.06E+05 1.48E−02 0.78 16.34 Y
    B08_7G8 FokI 9.16E+05 1.51E−02 0.77 16.48 Y
    H05_6A6 FokI 6.65E+03 1.17E−04 98.74 17.59 Y
    F07_7B11 FokI 6.60E+05 1.75E−02 0.66 26.52 Y
    A01_1A4 FokI 7.66E+05 2.05E−02 0.56 26.76 Y
    A09_9D1 FokI 5.85E+05 2.74E−02 0.42 46.84 Y
    G04_4F11 FokI 6.99E+03 3.32E−04 34.80 47.50 Y
    H01_1F12 FokI 4.30E+03 2.10E−04 55.01 48.84 Y
    E07_7A11 FokI 5.23E+05 2.60E−02 0.44 49.71 Y
    H02_2E8 FokI 9.54E+03 4.78E−04 24.17 50.10 Y
    C03_3D1 FokI 5.27E+05 3.56E−02 0.32 67.55 Y
    E04_4D4 FokI 2.45E+05 <8.55E−05  >135 <0.35 Y
    F04_4D12 FokI 2.42E+05 <8.55E−05  >135 <0.35 Y
    C04_4C6 FokI 9.12E+04 <8.55E−05  >135 <0.94 Y
    A08_7F11 FokI 7.57E+04 <8.55E−05  >135 <1.13 Y
    D08_8D2 FokI 7.23E+04 <8.55E−05  >135 <1.18 Y
    F05_5G9 FokI 6.45E+04 <8.55E−05  >135 1.33 Y
    E05_5F5 FokI 5.84E+04 <8.55E−05  >135 <1.46 Y
    B04_4B11 FokI 4.81E+04 <8.55E−05  >135 <1.78 Y
    C08_8C7 FokI 4.81E+04 <8.55E−05  >135 <1.78 Y
  • Purified antibodies shown in Table 4 below were chosen for further analysis and assay development.
  • TABLE 4
    Summary of antibody panel
    Binds
    FokI or
    t1/2 TALEN Western
    Ligand Analyte ka (1/Ms) kd (1/s) (min) KD (nM) (Y/N/A) ELISA Blot
    2299.2G3.C6 FokI 1.77E+04 <8.55E−05  >135 <4.83 Y + +
    2299.5D4.C8 FokI 1.12E+04 <8.55E−05  >135 <7.63 Y + +
    2299.6B3.B8.B6 FokI 9.87E+03 <8.55E−05  >135 <8.66 Y + +
    2299.6G5.C7 FokI 5.27E+03 <8.55E−05  >135 <16.2 Y + +
    2299.7F11.B4 FokI 7.57E+04 <8.55E−05  >135 <1.13 Y + +
    2296.14H5.C10 FokI 1.39E+03 6.81E−04 16.96 489.93 Y +/− −
    2296.17B5.A4 FokI 8.33E+04 9.40E−04 12.29 11.28 Y + −
    2296.23D1.B2 FokI 2.31E+03 6.31E−04 18.31 273.16 Y +/− −
    • Equivalents and Scope
  • Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the present disclosure as described herein. The scope of the present disclosure is not intended to be limited to the above description, but rather as set forth in the following claims.

Claims (42)

What is claimed is:
1. An anti-TALEN antibody comprising a variable heavy chain amino acid sequence that is at least 85% identical to SEQ ID NO: 3 and a variable light chain amino acid sequence that is at least 85% identical to SEQ ID NO: 7.
2. The anti-TALEN antibody of claim 1, wherein the antibody is humanized.
3. The anti-TALEN antibody of claim 1 or 2, wherein the antigen binding molecule is selected from the group consisting of an antibody, an scFv, a Fab, a Fab′, a Fv, a F(ab′)2, a dAb, a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a polyclonal antibody, a recombinant antibody, an IgE antibody, an IgD antibody, an IgM antibody, an IgG1 antibody, an IgG1 antibody having at least one mutation in the hinge region, an IgG2 antibody an IgG2 antibody having at least one mutation in the hinge region, an IgG3 antibody, an IgG3 antibody having at least one mutation in the hinge region, an IgG4 antibody, an IgG4 antibody having at least one mutation in the hinge region, an antibody comprising at least one non-naturally occurring amino acid, and any combination thereof.
4. The anti-TALEN antibody of any one of claims 1-3, wherein the antibody comprises a variable heavy chain (HC) selected from the group consisting of SEQ ID NOs: 3-6.
5. The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR1 selected from the group consisting of SEQ ID NOs: 12-14.
6. The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR2 selected from the group consisting of SEQ ID NOs: 15-20.
7. The anti-TALEN antibody of any one of the preceding claims, comprising a heavy chain CDR3 comprising SEQ ID NO: 21.
8. The anti-TALEN antibody of any one of the preceding claims, wherein the heavy chain comprises a heavy chain CDR1, a heavy chain CDR2, and a heavy chain CDR3, each CDR comprising an amino acid sequence shown in Table 1c.
9. An anti-TALEN antibody comprising a VH amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VH of an antigen binding molecule of claim 4.
10. The anti-TALEN antibody any one of claims 1-9, wherein the isolated antibody comprises a light chain variable region (VL) sequence selected from the group consisting of SEQ ID NOs: 7-11.
11. The anti-TALEN antibody of claim 10, comprising a light chain CDR1 comprising SEQ ID NOs: 22.
12. The anti-TALEN antibody of claim 10, comprising a light chain CDR2 selected from the group consisting of SEQ ID NO: 23-25.
13. The anti-TALEN antibody of claim 10, comprising a light chain CDR3 selected from the group consisting of SEQ ID NOs: 26-28.
14. The anti-TALEN antibody of claim 10, wherein the light chain comprises a light chain CDR1, a light chain CDR2 and a light chain CDR3, each CDR comprising an amino acid sequence in Table 1d.
15. An anti-TALEN antibody, comprising a VL amino acid sequence that is at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a VL of an antigen binding molecule of claim 10.
16. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 23; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26.
17. The anti-TALEN antibody of claim 16, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 7.
18. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27.
19. The anti-TALEN antibody of claim 18, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 8.
20. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 13;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26.
21. The anti-TALEN antibody of claim 20, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 9.
22. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 28.
23. The anti-TALEN antibody of claim 22, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 5; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 10.
24. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 17;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27.
25. The anti-TALEN antibody of claim 24, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 6; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 11.
26. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 15;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 24; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 27.
27. The anti-TALEN antibody of claim 24, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 3; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 8.
28. An anti-TALEN antibody, comprising
(a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO: 12;
(b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO: 16;
(c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO: 21;
(d) a VL CDR1 comprising the amino acid sequence of SEQ ID NO: 22;
(e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO: 25; and
(f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO: 26.
29. The anti-TALEN antibody of claim 24, comprising
(a) a VH comprising the amino acid sequence of SEQ ID NO: 4; and
(b) a VL comprising the amino acid sequence of SEQ ID NO: 9.
30. The anti-TALEN antibody of any of claims 1-29, wherein the isolated antibody further comprises a detectable label.
31. The anti-TALEN antibody of claim 30, wherein the detectable label is selected from the group consisting of a fluorescent label, a photochromic compound, a proteinaceous fluorescent label, a magnetic label, a radiolabel, and a hapten.
32. The anti-TALEN antibody of claim 31, wherein the fluorescent label is selected from the group consisting of an Atto dye, an Alexafluor dye, quantum dots, Hydroxycoumarin, Aminocouramin, Methoxycourmarin, Cascade Blue, Pacific Blue, Pacific Orange, Lucifer Yellow, NBD, R-Phycoerythrin (PE), PE-Cy5 conjugates, PE-Cy7 conjugates, Red 613, PerCP, TruRed, FluorX, Fluorescein, BODIPY-FL, Cy2, Cy3, Cy3B, Cy3.5, Cy5, Cy5.5, Cy7, TRITC, X-Rhodamine, Lissamine Rhocamine B, Texas Red, Allophycocyanin (APC), APC-Cy7 conjugates, Indo-1, Fluo-3, Fluo-4, DCFH, DHR, SNARF, GFP (Y66H mutation), GFP (Y66F mutation), EBFP, EBFP2, Azurite, GFPuv, T-Sapphire, Cerulean, mCFP, mTurquoise2, ECFP, CyPet, GFP (Y66W mutation), mKeima-Red, TagCFP, AmCyan1, mTFP1, GFP (S65A mutation), Midorishi Cyan, Wild Type GFP, GFP (S65C mutation), TurboGFP, TagGFP, GFP (S65L mutation), Emerald, GFP (S65T mutation), EGFP, Azami Green, ZsGreen1, TagYFP, EYFP,Topaz, Venus, mCitrine, YPet, TurboYFP, ZsYellow1, Kusabira Orange, mOrange, Allophycocyanin (APC), mKO, TurboRFP, tdTomato, TagRFP, DsRed monomer, DsRed2 (“RFP”), mStrawberry, TurboFP602, AsRed2, mRFP1, J-Red, R-phycoerythrin (RPE), B-phycoeryhring (BPE), mCherry, HcRed1, Katusha, P3, Peridinin Chlorophyll (PerCP), mKate (TagFP635), TurboFP635, mPlum, and mRaspberry.
33. The anti-TALEN antibody of claim 32, wherein the fluorescent label is R-Phycoerythrin (PE) or Allophycocyanin (APC).
34. A composition comprising the anti-TALEN antibody of any one of claims 1-33 and a pharmaceutically acceptable carrier or vehicle.
35. A polynucleotide encoding the heavy chain of an anti-TALEN antibody of any one of claims 1-29.
36. A polynucleotide encoding the light chain of an anti-TALEN antibody of any one of claims 1-29.
37. A vector comprising the polynucleotide of claim 35 or claim 36. 38. A cell comprising one or both of the vectors of claim 37.
39. The cell of claim 38, wherein the cell comprises a cell selected from the group consisting of a CHO cell, a Sp2/0 cell, a rabbit cell and an E. coli cell.
40. A method of making an anti-TALEN antibody of claims 1-29 comprising incubating the cell of claim 39 under suitable conditions.
41. A method of determining the presence or absence of a TALEN protein in a sample, comprising contacting the sample with an anti-TALEN antibody conjugated to a detectable label and determining the presence or absence of the TALEN protein in the sample.
42. The method of claim 41, wherein the anti-TALEN antibody comprises an antibody of any one of claims 1-33 or a humanized form thereof.
43. The method of claim 41 or 42, wherein the sample is a tissue sample, a blood sample, a formalin-fixed sample, a tissue grown ex vivo or cell culture media.
US18/354,037 2019-06-13 2023-07-18 Anti-talen antibodies and uses thereof Pending US20240003056A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US18/354,037 US20240003056A1 (en) 2019-06-13 2023-07-18 Anti-talen antibodies and uses thereof

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861214P 2019-06-13 2019-06-13
US16/900,602 US11781248B2 (en) 2019-06-13 2020-06-12 Anti-TALEN antibodies and uses thereof
US18/354,037 US20240003056A1 (en) 2019-06-13 2023-07-18 Anti-talen antibodies and uses thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US16/900,602 Division US11781248B2 (en) 2019-06-13 2020-06-12 Anti-TALEN antibodies and uses thereof

Publications (1)

Publication Number Publication Date
US20240003056A1 true US20240003056A1 (en) 2024-01-04

Family

ID=73745889

Family Applications (2)

Application Number Title Priority Date Filing Date
US16/900,602 Active 2041-11-13 US11781248B2 (en) 2019-06-13 2020-06-12 Anti-TALEN antibodies and uses thereof
US18/354,037 Pending US20240003056A1 (en) 2019-06-13 2023-07-18 Anti-talen antibodies and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US16/900,602 Active 2041-11-13 US11781248B2 (en) 2019-06-13 2020-06-12 Anti-TALEN antibodies and uses thereof

Country Status (12)

Country Link
US (2) US11781248B2 (en)
EP (1) EP3983435A4 (en)
JP (1) JP2022536341A (en)
KR (1) KR20220020905A (en)
CN (1) CN113993891A (en)
AU (1) AU2020291939A1 (en)
BR (1) BR112021025029A2 (en)
CA (1) CA3138501A1 (en)
IL (1) IL288807A (en)
MX (1) MX2021015057A (en)
SG (1) SG11202112553WA (en)
WO (1) WO2020252381A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4008347A4 (en) 2019-08-01 2023-03-08 Mie University Gd2 binding molecule

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (en) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab and its variants and immunochemical derivatives including immotoxins
US5869619A (en) 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
US6242568B1 (en) 1994-01-18 2001-06-05 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
USRE45721E1 (en) 1994-08-20 2015-10-06 Gendaq, Ltd. Relating to binding proteins for recognition of DNA
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6410248B1 (en) 1998-01-30 2002-06-25 Massachusetts Institute Of Technology General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
CA2491864C (en) 2001-07-12 2012-09-11 Jefferson Foote Super humanized antibodies
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
SG10201508995QA (en) 2005-07-26 2015-11-27 Sangamo Biosciences Inc Targeted integration and expression of exogenous nucleic acid sequences
JP5374360B2 (en) * 2007-02-27 2013-12-25 中外製薬株式会社 Pharmaceutical composition comprising anti-GRP78 antibody as an active ingredient
KR101748707B1 (en) * 2009-11-27 2017-06-20 삼성전자주식회사 c-Met specific antibodies and diagnosis kit for cancer using thereof
WO2011101328A2 (en) * 2010-02-18 2011-08-25 Roche Glycart Ag Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
WO2013091903A1 (en) * 2011-12-22 2013-06-27 Novo Nordisk A/S Anti-crac channel antibodies
WO2013093122A2 (en) * 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
US10196438B2 (en) * 2013-04-15 2019-02-05 Janssen Vaccines & Prevention B.V. Human antibodies binding to RSV G protein
US10011850B2 (en) 2013-06-21 2018-07-03 The General Hospital Corporation Using RNA-guided FokI Nucleases (RFNs) to increase specificity for RNA-Guided Genome Editing
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
JP2016536021A (en) 2013-11-07 2016-11-24 エディタス・メディシン，インコーポレイテッド CRISPR-related methods and compositions with governing gRNA
CN106573986A (en) * 2014-07-29 2017-04-19 豪夫迈·罗氏有限公司 Multispecific antibodies
FR3034420A1 (en) * 2015-03-31 2016-10-07 Lab Francais Du Fractionnement ANTI-CD303 MONOCLONAL ANTIBODIES

Also Published As

Publication number Publication date
JP2022536341A (en) 2022-08-15
WO2020252381A2 (en) 2020-12-17
IL288807A (en) 2022-02-01
AU2020291939A1 (en) 2021-12-02
CN113993891A (en) 2022-01-28
US11781248B2 (en) 2023-10-10
SG11202112553WA (en) 2021-12-30
EP3983435A4 (en) 2023-03-08
MX2021015057A (en) 2022-01-18
US20200392252A1 (en) 2020-12-17
CA3138501A1 (en) 2020-12-17
KR20220020905A (en) 2022-02-21
EP3983435A2 (en) 2022-04-20
WO2020252381A3 (en) 2021-03-11
BR112021025029A2 (en) 2022-01-25

Similar Documents

Publication Publication Date Title
US11572552B2 (en) Sortase
US9598492B2 (en) Human monoclonal antibodies specific for CD22
US20240003056A1 (en) Anti-talen antibodies and uses thereof
JP2019146571A (en) Anti-integrin β1 antibody composition and method of use
TW200823293A (en) Novel anti-Notch3 antibodies and their use in the detection and diagnosis of disease
JP6618539B2 (en) Method for enzyme-mediated polypeptide conjugation using sortase
US11162088B2 (en) Production of thioesters using sortase
JP2019508402A (en) Thiol-based deep eutectic solvent
US20070237772A1 (en) Tumor association of mdl-1 and methods
JP6605606B2 (en) Enzyme one-pot reaction for double polypeptide conjugation in a single step using sortase
US20180216091A1 (en) Novel soluble sortase a
Chen et al. LGR5 targeting molecules as therapeutic agents for multiple cancer types
WO2023009985A1 (en) Compositions and methods for in vivo protease profiling by immune cell display
CN117295767A (en) Antibody variants directed against WNT receptor RYK

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION